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ABSTRACT 
 
Microchimerism refers to one individual harboring cells or DNA at a low level that 
derive from another individual. The most common source is pregnancy when cells from 
the fetus and the mother pass the placenta bidirectionally, and give rise to maternal 
microchimerism (cells from the mother in the fetus) and fetal microchimerism (cells 
from the fetus in the mother). The cells persist in the individual, at least until middle-
age. Several hypotheses have addressed the consequences of harboring semiallogeneic 
cells. Both maternal and fetal cells within the host are associated with certain 
autoimmune diseases, as inducers of the disease but also as repairers of already injured 
tissue. Furthermore, inducing fetal-maternal tolerance during pregnancy seems to be an 
important purpose of the cell-trafficking. Observations from the transplantation field 
yield that this effect may be long lasting. 
 
In paper I, we examined the presence of maternal cells within different cellular subsets 
in tissues from eleven 2nd trimester fetuses. Seven fetuses presented with maternal 
microchimerism. The cells were widely spread in different tissues and found in both 
normal fetuses and fetuses with trisomy 21. The cells were of mature immunological 
and hematopoietic stem cells character.  
 
Paper II aimed to examine maternal microchimerism in healthy children’s tonsils and 
adenoid by a quantitative PCR assay. We found maternal microchimerism in four of 20 
children. The children were between four and six years old and harbored maternal cells 
in the tonsils and/ or adenoid at levels that ranged from 2 x10-2 to 7.1 x10-5. The same 
children were also positive for maternal cells in peripheral blood. 
 
In paper III, we investigated the association between maternal microchimerism in 
peripheral blood and systemic lupus erythematosus. In the study, 32 nulligravida 
women with SLE were included. Seventeen brothers of the women and additional 12 
unrelated males constituted healthy controls. Two patients and one control appeared 
with maternal cells in peripheral blood. The result indicates no correlation between 
maternal microchimerism in blood and SLE (P-value = 0.65). At a follow up, the same 
individuals tested negative 16 years after the first draw date. 
 
  
 
The purpose of paper IV was to evaluate the cellular subset and frequency of maternal 
cells in umbilical cord blood following vaginal deliveries and caesarian sections, when 
the time of umbilical cord clamping was known.  We included 44 babies from normal 
term pregnancies who were delivered vaginally (24) and by caesarian section (20). Five 
of 44 (11%) of the umbilical cord blood samples contained maternal microchimerism. 
The positive fractions were total DNA, CD34+ and CD56+. Four of the five positive 
samples were from caesarian sections and one was from a vaginal delivery. The 
positive samples were from deliveries with a mean clamping time of 37 seconds 
compared to 54 seconds in the negative group. 
 
Overall, we have shown that maternal cells are common in fetuses, infants and children. 
Their nature is of mature immunological and hematopoietic stem cell character. There 
is no correlation between the autoimmune disorder SLE, and maternal microchimerism. 
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1 INTRODUCTION 
 
 
This thesis is about how your mother may influence you from inside. 
 
"…a thing of immortal make, not human, lion-fronted and snake behind, a goat in the 
middle and snorting out the breath of the terrible flame of bright fire…” Homer’s 
description in the Illiad is the earliest description of the animal chimera which has its 
origin in the Greek mythology (1). In medicine, a chimera is defined as an individual that 
harbors foreign cells or DNA. When the number of cells is small the term microchimerism 
(Mc) is used.  
A microchimeric state may arise after a blood transfusion, an organ transplant or after 
hematopoietic stem cell transplantation (HSCT) (2,-4). However, the most common source 
of Mc is not from iatrogenic interventions, but from pregnancy when cells or DNA from 
the mother and the fetus pass bidirectionally over the placenta and result in maternal 
(MMc) and fetal Mc (FMc) respectively (5). This observation raises many imperative 
questions. Cells of fetal or maternal origin will be semiallogeneic in relation to the host 
(mother and offspring, respectively), and as such would be anticipated to evoke an 
immune response (6). 
The Nobel Prize winner in medicine and physiology in 1960, the immunologist Peter 
Medawar asked in an article from 1953: “how does the pregnant mother contrive to 
nourish within itself, for many weeks or months, a fetus that is an antigenically foreign 
body?” (7). He proposed in his article three theories that could explain this immunological 
wonder: 
 
1. An anatomical, impermeable barrier- the placenta- separates the fetus from the 
mother.  
This notion had been prevailing for long despite Schmorl reporting already in 1893 
about the findings of trophoblasts in the maternal pulmonary circulation (8). However, in 
the 1907 edition of William’s Textbook of Obstetrics it could be read: “The foetal blood 
in the vessels of the choronic villi at no time gains access to the maternal blood in the 
intervillous spaces” (9). Later, 1959, trophoblasts were also observed in the maternal 
blood. (10). Walknowska was first to report, in 1969, about fetal lymphocytes in the 
maternal circulation of pregnant women (11). Already at that time, the authors 
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speculated if the findings could be useful for prenatal diagnostics. In the early 1960s, 
fluorescently or radioisotopically labeled cells were injected into the mothers prior to 
parturition, and were thereafter detected in cord blood of their infants - the first evidence 
of maternal microchimerism was displayed (12, 13). 
 
Thus, the first theory of Medawar has been proved wrong and it is now well accepted 
that there is a bidirectional exchange of cells over the placenta during pregnancy and 
that the semiallogeneic cells may persist in the offspring and the mother for years (14, 
15). This fact make the immunological wonder of pregnancy even more fascinating 
since it has been proven that  the mother and fetus actually “see” each other during the 
nine months and later in life. 
 
The second theory presented by Medawar went as follow: 
 
2. The fetus is immunologically immature. 
 
A growing body of evidence showed that this hypothesis is not sufficient to explain 
why the fetus does not reject its mother. An early experiment by Billingham et al. 
showed that fetal chicks and mice who were exposed to foreign antigens in utero 
tolerated a skin graft from the same donor better, compared to those who were not 
previously exposed (16). Recent research has shown that the fetus is capable to create 
tolerance by inducing CD4+ cells to become regulatory T cells, and thereby achieve 
tolerance to self and to the non-inherited maternal antigens of maternal chimeric cells 
(17). 
 
 
The last theory concerned the immune system of the pregnant woman:  
 
3. The immune system of the mother is inert. 
 
Today it is well known that fetal antigens elicit both a cellular and humoral response in 
the mother although she obtains tolerance towards them during pregnancy (18). The 
tolerance could be long-lived or transitory (19, 20). Recently, indirect evidence that 
recipients in umbilical cord blood transplantation (UCBT) might benefit from cellular 
responses from maternal microchimeric cells in the transplant if the recipient and donor 
shared the same inherited paternal antigen (21). 
Regulatory T cells (T regs), actively induced, also seem to contribute to the maternal 
tolerance (22). 
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Historically, the consequences of pregnancy related Mc were first focused on FMc 
due to the fact that many autoimmune diseases have a female dominance and that 
autoimmune diseases generally have a peak incidence during and after childbearing 
age. Additionally, the striking resemblance of chronic graft-versus-host disease 
(GvHD) to certain autoimmune diseases such as systemic sclerosis (SSc) inspired the 
theory that diseases that had traditionally considered as autoimmune processes might 
in fact have an alloimmune component. This hypothesis was first formulated in 1996 
by Lee Nelson: “Is some autoimmune disease auto-alloimmune or allo-autoimmune?” 
(23). The microchimeric cells residing in an individual following a pregnancy will be 
semi allogeneic and as such would be expected to elicit an immune response. The 
hypothesis has now included MMc and autoimmunity and several diseases in children 
have been associated with persistent maternal cells. Briefly, three questions are asked 
in this context: Do maternal cells attack host cells? Are maternal cells the target of an 
attack? Are maternal cells homing to repair damaged tissue? 
However, MMc is common in healthy individuals; in cord blood, peripheral blood of 
children and adults and in tissues.  
 
 
In this thesis I will in the first chapters briefly discuss the anatomical and 
physiological features of the permeable “membrane” between the mother and the 
fetus i.e. the placenta. Thereafter, I will summarize the concept of transplantation 
immunology because of its parallels to the circumstances of the”transplanted” fetus. 
Finally, before the summary of the research addressing naturally acquired 
microchimerism, I will discuss the immunological events in the placenta, the mother 
and the fetus during pregnancy. 
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2 BACKGROUND 
 
2.1 THE PLACENTA 
 
The placenta constitutes the maternal-fetal interface and provides many functions 
throughout pregnancy, including the transportation of fetal nutrients and metabolic 
products as oxygen and carbon dioxide. It also produces numerous hormones and 
enzymes which are released into the maternal blood. 
The placenta consists of one fetal part - the umbilical cord, the fetal membranes 
(amnion and chorion) and the chorionic villi – and one maternal part, i.e. the decidua. 
Figure 1. 
Figure 1. The placenta 
During the first gestational week two types of cells develop from the fertilized ovum. 
The outer layer is covered by one layer of ectodermal cells, the primitive trophoblast, 
except at one pole where the rapidly dividing cells have formed the inner cell mass, 
which constitutes the beginning of the embryo. The invasive capacity of trophoblastic 
cells makes the blastocyst descend into the endometrium around day six or seven post 
fertilization. After implantation mesodermic cells grow out beneath the primitive 
trophoblast and form villi. Each villous consists of a mesodermic core covered by two 
layers of trophoblastic cells (24, 25). The outer cells are called syncytiotrophoblasts 
whereas the inner cells are termed cytotrophoblasts. Figure 2. The cytotrophoblasts 
decrease in number as pregnancy progresses.The syncytiotrophoblast is a 
multinucleated continuous cell layer that covers the surface of the placenta. It forms as 
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a result of differentiation and fusion of the underlying cytotrophoblast, a process that 
continues throughout placental development and by that contributes to the barrier 
function of the placenta. The extravillous trophoblast arises from proliferating cell 
columns and penetrates deep into the endometrium and the walls of the uterine wall. 
Invasive extravillous trophoblast plays an active role in the remodeling processes that 
occur in the uterine spiral arteries (24, 25). Pools of maternal blood, known as lacunae, 
surround and develop within the trophoblastic syncytium. Throughout pregnancy, the 
two circulatory systems remain separate. During the third week villi become united 
with maternal vessels that communicate with the intervillous space. Not until the end of 
the fourth gestational week, connections are made between the vessels of the chorionic 
plate and those of the fetus. 
 
 
2.1.1 Cellular traffic across the placenta 
 
Maternal or fetal cells passing across the placental barrier must migrate both through 
the fetal capillary endothelial cell layer and the trophoblast cell layers. The mechanism 
by which this happens is uncertain. Dawe et al. hypothesized in a review about possible 
Figure 2. Details of the placenta. 
AF= amniotic fluid  
CP= chorion plate  
DD=deciduas     
IVS=intervillous space  
MY=myometrium 
SA= spiral arteries  
UC=umbilical cord  
VT=villi tree         
 
AV= anchoring villi  
CTB= subsyncytial cytotrophoblasts  
EVT= extravillous cytotrophoblast 
FV=floating villi 
STR=stroma   
SYN= syncytiotrophoblasts 
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explanations which include 1) microtraumatic hemorrhage of the placental blood 
channels 2) specific cell types being capable of adhesion to the trophoblasts and of the 
walls of the fetal blood channels and migrate through the placental barrier created by 
the trophoblasts 3) deportation of trophoblast lining the maternal vessels and 
intervillous space into the maternal circulation (FMc) (26).  
Previous research that supports the first theory include the discovery of intervillous 
thrombi containing mixed maternal and fetal cells in the human and rodent placenta, 
and the finding of histological defects in the continuity of the trophoblast  lining (27, 
28, 29). The incidence of transplacental bleeding and if there is a certain time this 
happens during pregnancy it is not known (30, 31). Massive fetomaternal transplacental 
hemorrhage may have subsequent adverse outcomes for the neonate. It is not 
uncommon and it confirms the occurrence of events with defect trophoblast lining (32). 
The appearance of trophoblasts in maternal blood may also be explained by “the 
microtraumatic theory”.  
The second theory, presented by Dawe et al., includes active adhesion and 
transmigration of lymphocytes with help from special cell adhesion molecules 
including PECAM-1 and ICAM-1, which are expressed in the fetal capillary 
endothelial cell layer (33, 34). Trophoblasts also express ICAM-1 and other adhesion 
molecules (35). The authors hypothesized that the transfer of microchimeric cells might 
resemble the migration of cells that occurs across high endothelial venule endothelium 
in peripheral lymph nodes and at the blood-brain barrier (26). 
By term most cytotrophoblast and syncytiotrophoblast are replaced by a very thin (1-2 
µm) vasculosyncytial membranethat contains transtrophoblastic channels or pores that 
may also explain Mc exchange between mother and fetus (36).  
 
2.2 TRANSPLANTATION IMMUNOLOGY 
 
2.2.1 Major histocompability complex (MHC) 
 
MHC is a cell surface molecule group encoded by a large polymorphic gene family 
located on chromosome six and consisting mainly of two types, MHC I and II (37). 
Their main function is to mediate interactions of leukocytes, for example to present 
antigens to the T cells. In humans they are called human leukocyte antigen (HLA) class 
I and II. All nucleated cells carry HLA class I (HLA-A, -B, -C) which present antigen 
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of intracellular origin (synthesized from self proteins or viral antigens) to CD8+ cells 
(cytotoxic T cells) (37). Class II molecules (HLA-DR, -DP, -DQ)  are expressed 
primarily on antigen presenting cells (APC), including dendritic cells and macrophages, 
and also on activated T cells and present antigen of extracellular origin to CD4+ cells 
(T helper cells) (38). A specific T cell recognizes only a few HLA class-peptide 
combinations but is dependent on them to be activated, a phenomenon known as MHC 
restriction. Certain HLA class I and class II genes are highly polymorphic; some have 
several hundred alleles. Furthermore, polymorphism of HLA class I heavy-chain genes 
and HLA class II α- and β- chain genes increases the variety and strengthen T cell 
immunity. Both the paternal and maternal inherited HLA genes are expressed 
simultaneously, contributing to the diversity of possible antigen recognition. At a 
population level, the diversity of HLA molecules is important to survive epidemic 
diseases but it also creates the main immunological barrier to clinical transplantation. 
Some HLA class II molecules particularly DR and DQ are associated with 
autoimmunity.  
In general, HLA antibodies are not naturally occurring but may develop as a 
consequence of encountered non-self HLA for example in  blood transfusion, 
pregnancy (paternally inherited antigens), or organ or tissue transplant. 
 
2.2.2 Minor histocomability antigens (mHags) 
 
mHags are polymorphic self-proteins presented as breakdown products in the context 
of HLA class I or class II molecules. They do not evoke immune reactions as strong as 
MHCs but they elicit an immune response due to allelic differences between humans 
and have been shown to play a role in transplantation and pregnancy. In HLA- matched 
HSCT mHags may provoke a GvHD or modulate graft rejection in organ 
transplantations. (40). Parous female donors of hematopoietic stem cells (HSCs) are 
more likely to elicit a GvHD in recipients compared to non-parous or male donors, 
explained by previous sensitization to Y chromosome mHag peptides (HY) with 
subsequent initiation of an HY-specific CD8+ T cell response (41). Approximately 50 
different mHags have been identified and they are encoded on the Y chromosome, and 
on many autosomes (42). The large number of mHags indicates that histo-
incompatibility between donors-recipients or mother-fetuses is not a rare event. In 
transplantation not only unfavorable immune responses to mHags are elicited; mHag-
specific donor T cells may mediate a graft-versus-leukemia effect (GvL) or graft-
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versus-tumor effect (43). This function can be of advantage by using donor T-cells 
specific for a certain mHag, whose expression is restricted to the GvL effect by 
isolating them from the recipient’s blood, expand them and then re-infuse them into the 
patient (44, 45, 46). The role of mHags in pregnancy will be further discussed in the 
chapter of Reproductive Immunology. 
 
2.2.3 Transplantation 
 
The genetic differences in the highly polymorphic HLA molecules are the dominant 
underlying cause of immune responses against transplanted tissue or organs. After 
organ transplantation, alloreactions developed by the recipient’s immune system are 
directed at the cells of the graft and may cause a transplant rejection or a host-versus-
graft reaction. In contrast, in HSCT, the recipient’s immune system has been destroyed 
and the major type of alloreaction arises from mature T cells in the graft and is directed 
towards cells in the host. A graft-versus-host reaction starts and leads, with varying 
degrees of severity, to GvHD in almost all patients who undergo a HSCT. The degree 
of disparity of HLA molecules between donor and recipient correlate to the risk of 
GvHD and host-versus-graft reactions (47). T cells recognize alloantigens via two 
different pathways; the direct and the indirect (48). The direct pathway of 
allorecognition implicates T cells recognizing alloantigens as intact molecules 
presented by donor antigen-presenting cells (APCs). In the indirect pathway, T cells 
recognize alloantigens presented by host APCs by direct interaction of their receptors 
with the donor HLA molecules. Figure 3. 
 
Figure 3. Direct and indirect allorecognition demonstrated. With kind permission from 
dr Tomo Saric. 
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HSC are used in both autologous (a patient is given back his own stem cells) and 
allogeneic (a patient receives another individuals stem cells) transplantations with the 
aim to reconstitute the hematopoietic cell lineages in patients with both malignant and 
non-malignant disorders (49). The sources of HSC may be different; bone marrow, 
mobilized stem cells from peripheral blood or umbilical cord blood (UCB). When 
considering an unrelated donor, matching of HLA class I A, B and C and HLA class II 
DR and DQ is of most importance (50). If the match of these genes is perfect, the over-
all survival rate is comparable to matched related donor HSCT (51). However, 
achieving this perfect match is rare. A prevailing ranking of what genes are more 
important is not established. Prior to the HSCT, the recipient is subjected to destruction 
of his or her immune system (conditioning) in order to create space for donor cells and 
to suppress the ability to react against the allograft. This can be accomplished by 
chemotherapeutic agents or by radiation.  Depletion of donor T cells by neutralizing 
antibodies in the graft is sometimes performed in order to prevent GvHD. The 
disadvantages however will be increased risks of graft failure and infections and less 
GvL effect (52). After the HSCT the patient’s immune system must be restored and 
different cells reconstituted with different velocity (53). Neutrophil granulocytes, used 
as a marker for engraftment, are recovered after 2-3 weeks, UCBT after 4 weeks, 
whereas T cells are not recovered until 3-6 months post transplantation (53). 
 
 
2.2.4 Umbilical cord blood transplantation (UCBT) 
 
In 1988, the first transplantation with cord blood was performed. The patient was a boy 
with Fanconi anemia who underwent UCBT with his sister as the donor (54). Since 
then, collection and storing of UCB in international cord blood banks has increased the 
availability of UCB as a source of stem cells for the treatment of both malignant and 
non-malignant disorders. One of several advantages with cord blood transplantations is 
the accessibility, through cord blood banks, when no HLA-matched donor is available. 
The risk for the donor is absent. However, recently clamping time (the time passing 
before cutting the cord after delivery) prolonged to three minutes has been shown to 
result in higher hematocrite and higher ferritin concentration up to four months of age, 
which may be beneficial to the child, compared to children with immediate clamping 
(55). This regime cannot be attained with clinical collection of UCB since the amount 
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of blood is too limited to enable retrieval of sufficient numbers of cells for 
transplantation. At the two centers for UCB banking in Sweden, Stockholm and 
Gothenburg, a compromise has been introduced; clamping time of one minute in 
vaginal deliveries and 30 seconds in caesarian sections. Furthermore, the risk of 
developing GvHD is reduced due to the naivety character of UCB (56). One mayor 
disadvantage of using UCB as a source of HSC is the limited number of stem cells, 
leading to slower engraftment and reconstitution of the immune system with increased 
infections as a consequence (57). Still, a beneficial feature of UCB is the content of 
CD34+ cells with high capacity to self-renewal and proliferation (58). The use of 
double cord blood units i.e. the use of two unrelated UCB units has partly counteracted 
the problem of limited number of cells (59). The GvL effect after UCBT does not seem 
to be decreased, despite the lower incidence of GvHD (58). 
 
2.2.5 Graft-versus-host disease (GvHD) 
 
Clinical manifestations of GvHD depend on the degree of donor-host 
histocompatibility. The immune system of the recipient is usually not destroyed 
completely but co-exists transiently with the donors. Bidirectional alloreactions result 
in GvHD, host-versus-graft and GvL effects. These effects are mainly carried out by 
CD8+T cells (60). Billingham formulated in 1966, three requirements necessary for 
GvHD in general: 1.The graft must contain immunologically competent cells 2. The 
recipient must express tissue antigens that are not present in the transplant donor. 3. 
The host must be incapable of rejecting the transplanted cells (61). Acute GvHD arises 
within 100 days and is characterized by a systemic, progressive attack on the cells of 
skin, liver and intestines. The reaction derives from mature T cells from the donor that 
interact with the recipient’s dendritic cells (direct pathway of recognition). Alloreactive 
T cells will be stimulated to divide and differentiate into effector cells under the 
influence of inflammatory cytokines (60). Acute GvHD affects up to 85% of patients 
after HSCT and depend on donor type, HLA disparity and prophylaxis of GvHD (62). 
Chronic GvHD usually develops after 100 days following HSCT and affects 
approximately 30-50% of long-time survivors; it resembles an autoimmune disease, 
including the development of antibodies directed to the allogeneic HLA molecules and 
it involves the indirect pathway of recognition (63, 64). Chronic GvHD affects almost 
any organ although liver, skin and mouth are the most common sites (65). 
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 In spite of HLA matching, GvHD may arise. This can be exemplified by male patients 
who receive HSC from their HLA identical sister. The sister may be previously 
sensitized to HY (mHags encoded on the Y chromosome) that could influence the 
outcome of HSCT (66). 
Both acute and chronic GvHD are treated with different immunosuppressive drugs. 
 
 
2.2.6 Graft-versus-leukemia effect (GvL effect) 
Alloreactive donor T cells are not only exerting negative reactions since they also have 
the capacity to react against tumor cells. The development of GvHD is thought to 
mirror the benefits of a GvL effect. Weiden et al. reported that patients who developed 
GvHD also had significantly lower relapse rates (67). By giving patients with leukemia 
donor lymphocytes infusion induction of remission can be achieved (68). Additionally, 
patients receiving T cell depleted grafts in order to prevent GvHD have been shown to 
have significantly higher relapse rates (69). Natural killer (NK) cells may also be 
effectors in GvL reactions. They are among the first to be reconstituted after HSCT and 
mediate cytotoxic effects without prior sensitization. (70).  
2.2.7 Non-inherited maternal antigen effect (NIMA effect) 
 
The theory that the natural acquisition of maternal cells by the fetus may lead to 
durable, maternal-specific tolerance is called the NIMA effect. The theory has been 
based on results from transplantation studies. Patients who receive many blood 
transfusions become highly sensitized and develop antibodies against almost all HLA-
alloantigens making it hard to find a cross-matched negative organ donor if needed. In 
a study by Claas et al. 50 % of 26 such highly sensitized renal-transplant patients failed 
to produce antibodies against mismatched NIMA but were capable of producing 
antibodies against non-inherited paternal antigens (NIPA) indicating that exposure to 
NIMA induce partial B cell tolerance in the offspring (71). When mice and chicks were 
exposed to allogeneic tissue suspensions in utero and later, as adults transplanted with 
skin from the donor strains, acceptance of the graft tissue was achieved in contrast to 
the animals who received the skin graft from another strain than that they had been 
exposed to in utero (16). The NIMA effect has clinical relevance; a human solid organ 
transplantation study reported that the survival of a haplotype- mismatched kidney 
allograft from a sibling donor was significantly better if the mismatched HLA 
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haplotype was maternal (NIMA), as compared with paternal (NIPA)-mismatched 
donor-recipient pairs. (72). A similar effect of NIMA has been seen in HSCT. A better 
transplantation outcome and less GvHD is achieved when patients receive HLA 
haploidentical stem cell transplants from mothers or NIMA-mismatched siblings 
compared to those from fathers or siblings without NIMA mismatch (73- 76). 
 
2.3 REPRODUCTIVE IMMUNOLOGY 
 
A goal of both the mother and the fetus during pregnancy is to achieve a tolerogenic 
state to the semi-allogeneic counterpart. Mainly, this is carried out in three areas; the 
immunological features at the maternal-fetal interface i.e. the placenta and the decidua 
and the adaptive mechanisms of the maternal and developing fetal immune systems. All 
three parts may be of interest to understand the trafficking and the maintenance of 
MMc and FMc. 
 
2.3.1 The maternal-fetal interface 
The maternal-fetal interface is a dynamic site that comprehends multiple cellular 
interactions in an environment rich in cytokines and hormones (77). The fetus itself 
does not come into direct contact with maternal tissue. It is the trophoblast that forms 
the interface between the maternal and fetal compartments. During the first trimester, in 
the hemochorial human pregnancy, fetal extravillous trophoblast cells penetrate deeply 
into the decidua that will elicit recruitment of maternal immune cells and the 
production of pro-inflammatory cytokines (78). All fetal trophoblasts lack Class I 
HLA-A and HLA-B as well as Class II molecules, instead the extravillous trophoblasts 
bear HLA-C, -E and -G (79). Through this unique HLA expression, extravillous 
trophoblasts are capable of interacting with receptors expressed by uterine NK cells 
(uNK), T cells subsets and macrophages, leading to inhibition or activation with the 
purpose to protect the trophoblasts from attacks by maternal cells, and thereby 
maintaining normal pregnancy (80, 81). HLA-G molecules seem to be of high 
importance for successful embryo implantation in pregnancy and allograft acceptance 
in transplantation (82, 83). 
The decidua is populated by a variety of maternal immune cells. The purpose of those 
cells is to support placenta development, inhibit attacks of maternal effector cells and to 
combat infections. In decidualized endometrium, in both non-pregnant and pregnant 
women, the primary leukocyte subpopulations are uNK cells, macrophages and T cells. 
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The specific role of uNK cells is not clear but it has been suggested that they regulate 
fetal trophoblast invasion and the uterine vascular changes for maximizing maternal 
blood flow through placenta (84). Macrophages constitute 20-30% of the leukocytes in 
the decidua and are believed to, beside their function as protectors and effectors against 
infections, be involved in implantation, placental growth and the development of 
maternal-fetal tolerance (85). Approximately 10–20% of leukocytes in the first-
trimester human decidua are T cells and within this population a very small proportion 
constitutes T regs (86). The function of decidual T cells is so far undefined but they 
seem to exhibit their function by cell–cell contact and suppression of T cell responses 
(87, 88). The secretion of human chorionic gonadotropin from the trophoblast appear to 
attract T regs to the fetal-maternal interface and to modulate their regulating function 
(89). 
An association between increased T cells and decreased T regs levels has been noted in 
spontaneous abortion (90, 91). A decreased proportion of decidual T regs in 
preeclampsia has also been reported (92). 
 
2.3.2 The maternal immune system 
 
Proliferating T helper cells that develop into mature CD4+ cells differentiate into two 
major subtypes of cells known as T helper (Th) 1 and Th2 cells that are defined by their 
function, cytokine production profiles and surface chemokine receptors. 
For long the alteration of cytokine profile termed, “the Th1/ Th2 shift”, seen in 
pregnant women was considered the main mechanism for achieving a tolerogenic state 
during pregnancy. It refers to the fact that the maternal immune system downregulates 
Th1-induced cellular immunity and enhances Th2-induced humoral responsiveness in 
pregnancy, with a subsequent increased levels of anti-inflammatory cytokines such as 
IL-4, IL-5, IL-10 compared to IFN-γ, TNF-α and IL-2 that are considered inflammatory 
(93, 94). Pregnancy related hormones such as progesterone, estradiol, leukaemic 
inhibitory factor and prostaglandins promote the Th2 profile (95-97). Trophoblasts also 
contribute to the Th2-cytokine dominance in pregnancy (98). 
More recent research suggests that the maternal immune system is aware of the semi-
allogeneic fetus and develops strategies to tolerate it. During pregnancy large amounts 
of apoptotic trophoblast are shed into the maternal circulation that can be captured by 
APCs that present fetal antigen to T cells but maternal tolerance is generally not 
compromised by these T cells, whose activity seem to be restricted by clonal deletion 
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or suppression (99). T regs are considered to mediate a large part of active immune 
tolerance that inhibits maternal lymphocytes from attacking the fetus (22). Recent data 
shows that T regs specific to fetal antigens expand more than 100-fold (100). In a 
mouse model depletion of T regs generated a higher rate of spontaneous abortions (22). 
The mechanism of how T regs contribute to the tolerogenic state of pregnancy has been 
proposed to be attributed to their secretion of IL-10 and PD-1 (programmed cell death 
protein 1) and by the up-regulation of IDO (indoleamin-pyrrole 2,3-dioxygenase) 
expression on dendritic cells and monocytes in peripheral blood and deciduas, leading 
to a local tolerant microenvironment and suppression of T effector cells (101-103). 
Interestingly, it seems that already the encounter with seminal fluid will stimulate the 
expansion of T regs as a preparation for pregnancy (104). 
T cells specific for at least three different mHags (HA1, HA2, HY) have been identified 
in women following pregnancy and may be detected decades afterwards (105-107). The 
mHag specific T cells are elicited during pregnancy and appear to be able to lyse target 
cells and produce IFN-γ (108). Three hypotheses by Linsheid et al. may explain why 
theses T cells do not cause rejection of the fetus; firstly, T cells are not fully activated 
during pregnancy and consequently are deficient in their effector function in vivo, 
secondly T regs at the maternal-fetal interface prevent rejection and thirdly, fetal-
specific T cells are unable to traffic to the maternal-fetal interface and thus cannot 
mediate their attack. (109). Both placenta and microchimeric fetal cells are likely 
sources of fetal mHags during pregnancy.  
 
2.3.3 The fetal immune system 
 
Less is known about how the immune system of a fetus deals with the challenges of 
developing in a semi-allogeneic host. In the past, the fetal immune system was 
considered inert and functionally impaired due to limited antigen experience, but recent 
research has confirmed that the human fetal immune system is decidedly active. The 
fetus must learn to tolerate benign antigens, including self-antigens as well as maternal, 
food and environmental antigens that cross the placenta. Given that the fetus is 
relatively protected against microbial infections inside the uterus and that the fetus, the 
premature and newborn has an enhanced susceptibility to infections, it makes sense that 
the developing fetal immune system mainly is tuned to generate tolerance.  
Heamatopoesis originates in the early yolk sac, but from the 11th-12th gestational week 
the liver is the primary organ of the fetal hematopoesis, whereas from the 20th 
 15 
 
gestational week heamatopoesis mainly resides in the bone marrow (110). With 
increasing gestational age the innate immune system of the fetus is formed. However, 
neonatal innate cells display fewer functions and produce less cytokines compared to 
adult (111). NK cells are also a part of the fetal developing innate immune system and 
have the capacity to detect and destroy virus infected cells through a cytotoxic 
mechanism. The levels increase through pregnancy and reach the maximum level at 
birth (approximately 10% of lymphocytes in cord blood). The levels then decrease to 
reach adult levels around the age of 5 years (112). Complement factors, contributing to 
the innate defense, are produced in the fetal liver, but in neonates they are reduced to 
10-70% of adult levels (l13). 
The adaptive immune defense, which is characterized by the elimination of specific 
pathogens and by development of an immunological memory, includes T cells and B 
cells. The levels of those cells increase with gestational age, but the first week after 
birth they expand immensely (114). T cells migrate from the fetal liver or bone marrow 
to mature in the thymus. The fetal thymus develops around the 9th-10th gestational week 
but is not mature until the14th-16th gestational week (115). In the thymus the genes of 
the T cell receptor rearrange, resulting in a large diversity of potential T cell antigen 
specifities. The T cells bearing receptors which recognize self-MHC on the epithelial 
cells are positively selected for differentiation to CD4+ or CD8+ single positive cells 
(116). The T cells leave the thymus as naïve CD4+ or CD8+ cells. In peripheral 
lymphoid tissues they get activated and start to mature by binding to their 
corresponding antigen/ HLA. Yet, this activation is dependent on co-stimulation of 
APCs. By 16th-20th gestational week T cell development is well under way and T cells 
migrate to the periphery (117). At the same gestational age the peripheral lymph nodes 
are colonized by lymphocytes (118). 
The fetal immune system needs not only to develop in order to be armed against 
infections after birth, it must also learn to tolerate benign and/or necessary antigens 
(including maternal). In the thymus, parallel to the positive selection of CD4+ cells and 
CD8+, the T cells whose receptor bind to self-antigen/ MHC and by that have a 
potential to be auto reactive, undergo apoptosis in a process known as clonal deletion 
(119). By that, central tolerance is achieved.  However, mature auto reactive T cells 
may escape from the negative selection in the thymus (120).  To deal with those 
escaping T cells that may exert potentially harmful autoimmune reactions in the 
individual, a secondary line of tolerance promoting exists in the periphery, imposed by 
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a population of regulatory T cells. The best characterized are the CD4+ CD25+FoxP3+ 
T regs. They are identified by their expression of transcription factor FoxP3 and the IL-
receptor α-chain (CD25) (121). They suppress immune responses through production 
of IL-10 and TGF-β (transforming growth factor β). Mouse studies have shown that 
depletion of the CD4+CD25+ T cells result in severe autoimmunity (121). An X-linked 
syndrome characterized by early onset of autoimmune disease in multiple organs was 
defined in humans in 1982. The syndrome, named IPEX (immune dysregulation, 
polyendocrinopathy, enteropathy, X-linked) was found to emerge from disruption of 
FoxP3 leading to the absence of T regs (123). The mechanism used by T regs includes 
binding to the same APC as the autoreactive T cell followed by secretion of non-
inflammatory cytokines, direct target-cell cytotoxicity and modulation of antigen 
presentation, and thereby inhibiting proliferation and activation of the T cell (124). The 
development of T regs starts approximately in the 13thgestational week, in the fetal 
thymus (125). Fetal lymph nodes in the second trimester contain a high amount of T 
regs (on average 15-20% of CD4+ cells) compared to adult lymph nodes, full-term cord 
blood and adult peripheral blood (less than 5% of CD4+ cells)(118, 126) Michaelsson 
et al. showed that depletion of T regs in the fetal lymph node generated a spontaneous 
proliferation of conventional T cells and increased production of IFN-γ upon 
stimulation, but not in the assays of T regs depletion in adult lymphnodes (118). This 
finding made the authors suggest that 1) fetal T cells are, in the absence of T regs, 
highly responsive and that T regs have a suppressive influence in the fetal immune 
system to achieve peripheral tolerance 2) adult and fetal adaptive immune systems 
exhibit significant differences with respect to the requirements for maintenance of 
peripheral tolerance (118).  
Based on these observations and the previous findings of MMc in fetuses, the same 
research group tested the hypothesis that fetal T cells could react on maternal antigen 
and the fetal immune response could be inhibited by fetal T regs (17). First of all, MMc 
was found at a rather high level (up to 0.8%) in fetal lymph nodes in 2nd trimester 
fetuses. Then fetal immune responses against maternal APC bearing NIMA and against 
unrelated, third party APC were tested in vitro by mixed lymphocyte reaction (MLR). 
Fetal responses against NIMAs were less prominent compared to unrelated antigens, 
indicating tolerance. When fetal cells were depleted of T regs prior to MLR, the 
immune response increased against maternal and self APC but not against unrelated 
donor alloantigen. Subsequent experiments were conducted on peripheral blood of 
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healthy children with the aim to investigate if T regs could suppress T cell activity 
against maternal or paternal APC. A small but significant suppression against maternal 
APCs compared to paternal was noted. It is not known if theses T regs orginated from 
fetal life or if they developed more recently due to ongoing MMc (17). 
In conclusion; it appears that fetal T regs are involved in the induction and maintenance 
of the NIMA effect. 
 
2.4 METHODS TO STUDY MICROCHIMERISM 
The technological challenges to study Mc are related to the limited number of cells, 
and therefore the identification requires sensitive methods. One strategy to identify 
fetal cells in a woman is the utilization of the Y chromosome as a marker to detect 
male cells in a female host (5,15). Fluorescent in-situ hybridization (FISH) with Y 
chromosome-specific probes can be used to microscopically identify male cells in 
blood or tissues. The practicality is however restricted by the time-consuming work 
of screening a very large amount of cells. FISH analysis can be combined with 
concomitant cellular phenotyping by immunohistochemistry (127). MMc may also be 
studied with FISH assays, by identification of female cells in male tissue or blood 
(127). Figure 4. 
 
Figure 4. Maternal epithelial cell in the lung identified by cytokeratin expression. X-
probe signal = red. Y-probe signal=green. With kind permission from dr Anne 
Stevens. 
DNA amplification using the polymerase chain reaction (PCR) provides a sensitive 
method to detect and quantify microchimeric cells. In certain assays the sensitivity 
can reach one donor cell per million host cells (128). DNA is extracted from tissues 
or peripheral blood and detected by targeting nonshared, maternal-specific HLA 
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polymorphism (129). Other variants of genetic polymorphism, including the use of 
markers for the Y chromosome in FMc assays, may also be used (130).   
2.5 FETAL MICROCHIMERISM 
 
2.5.1 Fetal microchimerism in blood and tissue 
 
In humans, fetal DNA has been detected in maternal blood as early as at four to five 
weeks of gestational age, and both fetal cells and DNA are consistently detected from 
seven weeks (131,132). In 2nd trimester pregnancies the number of circulating fetal 
cells in maternal blood is estimated to 2-6 per milliliter and distinctly increase until 
parturition with a rapid decline post partum (133,134). Free fetal DNA has been 
demonstrated to be much more frequent than fetal nucleated cells (100% vs. 26%) in 
the circulation of pregnant women and with a more rapid clearance (5). The 
discrepancy made Lo et al. speculate if the cell populations predominantly involved 
in cellular traffic and plasma DNA liberation are different, suggesting that the 
trophoblasts are the main source of liberated plasma fetal DNA and that persistent 
FMc would originate from intact fetal cells (5).  
 
Male hematopoietic stem cells, presumably fetal, have been demonstrated in the 
circulation of women decades after they had given birth to sons (15). The fact that the 
fetal cells persist may be explained by their ability to engraft in bone marrow as 
progenitor cells with the capacity to differentiate, proliferate and re-infiltrate blood 
and tissue later (135).  
Conditions associated with placental dysfunction appear to result in an increased 
passage of fetal cells into the mother. For example, in pregnancies complicated by 
abnormal fetal karyotype, Bianchi and others have shown that the levels of FMc was 
several times higher in pregnancies associated with trisomy 21compared to normal 
pregnancies (136, 137). Increased amounts of free fetal DNA in the maternal 
circulation have also been reported in preeclampsia and HELLP (hemolysis, elevated 
liver enzymes, and low platelets) as well as in preterm labour and fetal growth 
restriction( 138-141). Whether similarly high levels are present years later is currently 
unknown. 
The cellular subsets in FMc are various, with both mesenchymal and hematopoietic 
origin (142). Hematopoetic lineage markers have been demonstrated in subsets of 
CD3+, CD4+, CD8+, CD19+, CD14+,CD56/16, CD66b+ and CD34+(5, 143,144). 
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Y chromosome bearing cells have been identified in diverse female tissues, including 
thyroid, skin, lung, lymph nodes , kidney, liver, hearts, spleen, cervix, intestine and 
bone marrow (135, 145-151). Thus, it seems that fetal cells are widely spread within 
the body and become incorporated into a range of various cell types. Additionally, 
differentiated fetal cells have been demonstrated for example among hepatocytes, 
cardiomyocytes and thyrocytes (152-154). 
 
2.5.2 Fetal microchimerism in autoimmunity 
 
A maternal cellular immune response directed against fetal antigens can be detected 
in humans, suggesting that persisting FMc could be recognized by maternal T cells 
mediating an allo-autoimmune reaction (19,105, 106). So, the association between 
FMc and several disorders that traditionally have been referred to as autoimmune 
have been investigated, the first being SSc. SSc has clinical resemblance to chronic 
GvHD, including development of auto antibodies and has its peak incidence in 
women after reproductive years (155). Women with SS had significantly higher levels 
of male DNA in peripheral blood, detected by Y chromosome specific PCR, 
compared to healthy controls (156, 157).  Subsequent studies have reported 
comparable results, i.e. FMc is more prevailing in the peripheral blood mononuclear 
cells, skin lesions and other affected organs of women with systemic sclerosis (158, 
159). However, healthy controls also harbor FMc, and other studies have not clearly 
identified an association between SSc and FMc (160,161). 
Hypotheses regarding how FMc contributes to the disease include both a fetal vs. 
maternal type reaction (graft vs. host) and a maternal vs. fetal reaction (host vs. graft) 
(162). The maternal vs. fetal reaction is suggested to involve immune recognition of 
fetal cells by maternal T cells, either in a direct or an indirect way. In the direct way 
fetal antigens are presented directly by persistent fetal APC to maternal T cells, 
whereas in the indirect way, fetal antigens are presented to the maternal effectors by 
maternal APCs.  
Various other autoimmune diseases have been investigated for their association with 
FMc.  Fanning et al found male cells, presumably fetal, in liver biopsies from patients 
with primary biliary cirrhosis, but not in controls, whereas other studies did not found 
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any clear association.( 163-165). Fetal chimeric cells have been identified in affected 
salivary glands in patients with Sjogren’s syndrome, but not in peripheral blood 
(166,167). The study of autoimmune thyroid disease is of particular interest because 
of its frequent onset or relapse in the postpartum period, but, once again, study results 
have been controversial. Klintschar et.al found an increase in FMc in affected thyroid 
tissue of women with Hashimoto’s disease, but in the study by Srivitsa et al. similar 
frequency of FMc was detected in Hashimoto’s disease and thyroid neoplasms (145, 
168).  In conclusion, the association between FMc and systemic sclerosis appears to 
be the most clearly established. The role of the fetal cells remains controversial- are 
they an essential part of the pathogenesis or is the finding of fetal cells in affected 
tissues and the increased frequency in blood a manifestation of recruitment of fetal 
cells to damaged tissue, where they may take part in repair processes? 
The fact that FMc is present in a wide range of tissues, not only those affected by 
autoimmune processes, formulated the alternative hypothesis that the occurrence of 
fetal cells in these tissues is a result of the fetal cells homing to areas of damaged 
tissue participating in repair processes. Descriptions from the literature include: in a 
woman with hepatitis C, invading fetal cells with a mature liver phenotype were 
observed in the liver; the fetal cells were assumed to originate from a pregnancy 17 
years earlier (169). Well-differentiated liver cells of male origin were demonstrated in 
36% of liver biopsies from women with different hepatic diseases (149). Fully 
differentiated male thyroid have been observed in thyroid of a woman with 
autoimmune thyroid disease (145). Furthermore, synovial tissue of patients with 
rheumatoid arthritis contained fetal mesenchymal stem cells with possible ability to 
participate to bone and cartilage repair (170). The fact that FMc were more likely to 
be found in patients with a severe SLE compared to those with a mild variety 
formulated the theory that the fetal cells were not causing the disease but rather home 
to the damaged maternal tissue once the injury reaches a certain level (171). 
2.5.3 Fetal microchimerism in cancer 
Recent reports suggest an association between pregnancy, Mc and cancer. It is less 
likely that parous women who harbors FMc develop cancer than parous women 
without FMc suggesting a immunosurveillance and/ or tumor suppressor function, 
especially in breast cancer (172-174). Gadi proposed three mechanisms how the fetal 
microchimeric cell could contribute to alloreactivity against cancer antigens in the 
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mother: 1) fetal T cells effectors attack maternal, malignant cells expressing cancer 
antigens 2) fetal APCs present maternal cancer antigen to maternal effector cells 3) 
fetal NK-cells initiate a cytotoxic reaction towards the maternal malignant cells (175). 
Additionally, fetal cells in cervical, lung and thyroid cancer tissues have been 
demonstrated (176-178). However, it is hard to evaluate those findings; are the fetal 
cells effectors, an accompanying marker of concomitant process or providers of tissue 
repair?  
2.6 MATERNAL MICROCHIMERISM 
 
In the beginning of the eighties the idea that allogeneic maternal cells might be 
involved in triggering disease in children was born. Children affected with severe 
combined immunodeficient disease (SCID) were shown to harbor maternal cells in the 
circulation and the maternal cells were also engrafted in tissues (179). SCID is a genetic 
disorder characterized by the absence of functional T-lymphocytes. The defect immune 
system manifests by impaired antibody response due to either direct involvement with 
B lymphocytes or through improper B lymphocyte activation due to non-functional 
CD4+ cells. In a large cohort by Muller et al., as many as 40% of infants with SCID 
harbored engrafted maternal T cells and GvHD was developed in 76% of them (180). 
The phenotypes of the engrafted maternal chimeric cells in SCID infants have been 
confirmed to be T and B cells but without the ability to functionally replace the 
immune system of the infant (179-181). Since then, additional pediatric diseases have 
been proposed to be associated with MMc; juvenile dermatomyocytis (JDM), juvenile 
idiopathic inflammatory myopathies (JIIM), neonatal lupus syndrome (NLS), type 1 
diabetes, pityriasis lichenoides, biliary atresia (182-190).So far, one autoimmune 
disorder affecting adults has been shown to harbor MMc to a higher frequency; SSc 
(129). 
 
2.6.1 Maternal microchimerism in blood and tissue 
 
The fetal immune system has been shown to be exposed to maternal microchimeric 
cells from the 13th gestational week (in blood samples taken prior to induced abortions) 
(191). Studies in the 60ties detected MMc in cord blood by labeling maternal blood 
cells with a fluorescent dye or Chromium-51 and injecting them back into the mothers 
before delivery (12,13). More modern studies investigating MMc in cord blood have 
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shown very diverging results depending on the method (5,192-200). The frequency has 
varied greatly; 0% to 100% with a mean frequency of 14%.  
Maternal cells are also common in infants and healthy individuals and have been 
identified in the peripheral blood up to the age of 49 (14). Maloney et al. developed a 
PCR assay which could detect one maternal cell in the background of 100.000 host 
cells. In healthy offspring, DNA sequences, presumed to be maternal, were identified in 
17 (55%) of 31 individuals from the age of 9 to 49 years (14). Quantitative methods as 
quantitative real time PCR (QRT-PCR), have estimated the levels for example in cord 
blood to 2.6 x 10-4(5). The subsets of maternal cells in peripheral blood of healthy 
individuals were investigated by flow cytometry followed by QRT-PCR and were 
found to be CD3+ (T cells), CD19+ (B cells), CD 14+ (macrophages, monocytes), 
CD56+ (natural killer cells) (201). The study revealed a frequency of MMc of 39% in 
healthy individuals. Granulocyte populations also contain maternal cells (144). 
 Several studies have explored the tissue engraftment capacity of the maternal cells. In a 
2nd trimester fetus, MMc was found in a variety of tissues including liver, lung, heart, 
thymus, spleen, adrenal gland and kidney (202). The cells were of hematopoietic and 
stem cells origin. In infants with inflammatory and non-inflammatory diseases maternal 
cells were detected by FISH analysis for X- and Y-chromosomes in liver, pancreas, 
kidney, heart, lung, skin, thyroid and thymus (127, 203). Thus, MMc in tissues could 
conceivably be targets of an immunological attack.  
 
2.6.2 Maternal microchimerism in autoimmunity 
 
Maternal cells appear to have multi-linage plasticity since female (presumed to be 
maternal) cells expressed sacromeric α-actin, a marker for myocardial cells, in the heart 
tissue of male infants who died from NLS (187). The development of NLS starts in 
utero in fetuses of mothers with anti-SSA antibodies leading to congenital heart block, 
rash, hepatic and hematologic abnormatilities (204). Not all babies born of mothers 
with those antibodies develop the disease suggesting other pathological mechanisms. 
Using a FISH assay, MMc was demonstrated in 15 of 15 sections of NLS heart tissue, 
with a frequency range of 0,025% to 2,2% of total cells (187). In controls, only 2 of 8 
sections showed maternal cells (0-0,1% of total cells). Furthermore, 86% of the 
maternal cells expressed a marker for cardiac myocytes- sacromeric α-actin, indicating 
differentiating capacity. 
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Pityriasis lichenoides  
Pityriasis lichenoides is a skin disease that predominately affects children and young 
adults with unknown cause although some researchers have suggested that the initiation 
of the lesions could be viral (205). The clinical characteristics are flares of 
inflammatory skin lesions. Pathological findings include lymphocyte infiltration deep 
into the dermis with lymphocytes within the subsets of CD3+ and CD8+ (205). A study 
by Khosrotherani et al. demonstrated increased levels of maternal cells in skin tissue of 
male children with pityriasis lichenoides compared to healthy children, although the 
difference in frequency was not significant (189). Numbers of maternal cell were 99/ 
million in patients compared to 5/ million in controls (p=0.005). Combined FISH with 
immunostaining using anti-CD45 antibody was used on nine sections from patients and 
five from controls. None of the 19 chimeric cells stained positive with CD45+ but in 
seven of 10 patients the maternal cells stained positive for cytokeratin indicating that 
they had differentiated into keratinocytes. 
 
Type 1 Diabetes 
Type 1 Diabetes is characterized by autoimmune destruction of insulin secreting islet 
beta cells in pancreas leading to insulin deficiency and lymphocyte and macrophage 
infiltration. In children with diabetes, maternal cells were more frequent in peripheral 
blood compared to unaffected siblings and unrelated controls (188). By in situ analys, 4 
male pancreases were examined in regard to MMc. Few female, hematopoetic cells 
were found but female, insulin- positive cells, presumably β cells were detected at 
slightly higher levels in diabetic tissue compared to controls indicating ability to 
differentiate into a tissue specific phenotype. Since MMc not was found in the 
lymphocyte subset, the authors suggested that it was unlikely that the maternal cells act 
as effectors but the finding of insulin- positive chimeric cells could rather indicate a 
consequence of tissue repair (188). A similar study was conducted by Vanzyl et al. 
(206). They found maternal cells in pancreas, both in patients and controls but the 
frequency of cells was significant higher in patients. The maternal cells ranged between 
0.31 and 0.80%,mean 0.58% compared to controls;  0.24-0.50%, mean 0.38%) (p = 
0.05). The maternal cells were both insulin negative and insulin positive but CD 45+ 
was not expressed, indicating absence of effector function of microchimeric cells. 
The findings of differentiated maternal cells in tissues could be interpreted that they 
home to the area of damaged tissue and participate in a tissue repair process. 
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Juvenile dermatomyosytis 
JDM is a multi-organ autoimmune disease that causes inflammation in small vessels of 
muscles, skin and the gastrointestinal tract and has been associated with the HLA Class 
II allele DQA1*0501 (207). The pathogenesis remains unclear but muscle biopsies 
have demonstrated lymphocyte and phagocyte infiltration (208). Maternally derived 
cells have been shown to be more frequent both in muscle biopsies and in whole blood 
of children with JDM compared to controls (182, 183, 185). 
In a recent study by Ye et.al muscle biopsies from 7 male children with JDM and 4 
healthy male controls were investigated with FISH combined with confocal imaging 
(184). Concomitant immunofluoroscence for CD45+ was used to determine whether 
MMc in muscle were lymphocytes. The study confirmed previous results: the 
frequency of MMc was significantly higher in JDM muscle (0.42-1.14%) compared to 
controls (0.08-0.42%). Among the maternal cells no CD45+ cells were observed. Thus, 
the findings of differentiated maternal cells in tissues and with absence of maternal 
lymphocytes could be interpreted that they home to the area of damaged tissue and 
participate in a tissue repair process. 
Additionally, in the study of Reed et al. the presence of MMc in healthy subjects was 
shown to be associated with the HLA genotype of the mother, in particular HLA 
DQA1*0501 (184). 
 
Systemic sclerosis 
SSc is a chronic immunological disease characterized by increased accumulation of 
collagen in the skin and in various internal organs. Cellular infiltration constitutes 
above all of T cells. Like in FMc, there has been an association between MMc and the 
disease. MMc occurred more frequently among women with SSc (72%) compared to 
healthy controls (22%) but levels of maternal cells were not significantly different 
(129). However, in a patient negative for MMc in blood who then died from the 
disease, high levels of MMc was found in both affected and non-affected internal 
organs and bone marrow (129). 
 
Biliary atresia 
Several studies have exposed an association between biliary atresia (190, 209-211). It is 
an autoimmune, progressive disease of the biliary tree in infants and it is the most 
common cause of pediatric liver transplantation. Maternal CD8+ cells were more 
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frequently found in livers of patients with biliary atresia compared to controls and some 
maternal cells were cytokeratin-positive (211). 
In conclusion, studies of MMc and autoimmunity have its origin in the same reasoning 
as FMc and autoimmunity i.e. the similarities between chronic GvHD and some 
autoimmune diseases where maternal cells could act as effector cells in the progeny, for 
example as in JDM (183,185). Examples of conditions with a possible beneficial effect 
of MMc are NLS and type 1 diabetes where maternal cells appeared with tissue specific 
character in the absence of maternal inflammatory cells. (187, 188, 206). A theory that 
maternal cells may influence a fetal response towards self antigens has been proposed 
by Leveque et al. (212). 
The observation made in the transplantation field that incompatibility between HLA 
genes between patient and donor highly affects the risk to a patient to develop chronic 
GvHD have led to the hypothesis that naturally acquired microchimerism and 
developing of autoimmunity are dependent of the HLA combination of host and donor 
(156, 183). 
2.6.3 HLA and naturally acquired microchimerism  
 
HLA may affect the presence of Mc in different ways. First of all, a specific HLA allele 
in the mother or the child may influence the occurrence of FMc or MMc (156, 183).  
Secondly, a compatibility of HLA alleles from the perspective of the mother (regarding 
FMc) or the fetus (regarding MMc) may influence the ability of host cells to pass the 
placenta undetected and/or engraft. For example, increased levels of FMc have been 
described in SSc (156). Women with SSc had significantly more often given birth to a 
child compatible to the mother for HLA-DRB1, prior to disease onset (156). Berry et 
al. investigated the presence of MMc in cord blood, collected for a variety of medical 
reasons between gestational week 18 and 38 (200). MMc was detectable in 16 of 30 
samples. The frequency and concentration of MMc was higher when there was 
maternal compatibility for HLA-DQB1 from the fetal perspective, that is, the mother 
was DQB1 homozygous or HLA identical.  
Mother DQB1* DQB1*     Mother DQB1* DQB1¤  
Child DQB1* DQB1#    Child DQB1* DQB1¤  
 
The mother is DQB1 homozygous                              The mother is DQB1 identical 
Figure 5. Compatibility of the mother from the child’s perspective 
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Thirdly, a transfer of an autoimmune HLA risk allele through Mc may be possible: a 
study by Rak et al. showed that FMc may have an adverse effect in RA patients who 
lack the most common RA risk-associated HLA alleles, HLA-DRB1*04 and HLA-
DRB1*01 (213). An increased frequency and higher levels of FMc with those alleles 
were observed in patients with RA compared to controls. Related to MMc, on the other 
hand, several studies have demonstrated that patient with RA who lack HLA-
DRB1*04, have mothers with the risk allele (NIMA) to a higher frequency rather than 
fathers (NIPA) carrying this allele (214, 215). However, it was not investigated if 
patients with RA harbored MMc. 
Given the common incidence of MMc in healthy individuals it is logical to assume that 
the presence of MMc, or naturally acquired Mc as a whole, not always contribute to 
disease. So, the possible consequences of MMc range from tolerance to sensitization 
but what process might disrupt the balance it is not known. Maternal microchimeric 
cells, normally present at a low level might be expanded by an environmental stimulus 
and proliferate in blood and tissues. At higher levels MMc could reach the threshold for 
activation of the host’s immune system or become more prone to be effectors in an 
“alloimmune” process. Alternatively, the occurrence of the semi-allogeneic cells may 
reflect induction of host tolerance  
Very few studies have provided tests of MMc and its functions in humans. In the study 
by Reed et al. maternal T lymphocytes were isolated from children with JDM and were 
shown to react to the children’s cells in vitro by producing IFN-γ (183). In contrast, the 
maternal cells did not react to the healthy sibling. A case report describes a 21-year old 
male who was exposed to volatile chemicals in a tyre factory. He developed a condition 
with resemblance to GvHD including lymphocytic infiltrates and fibrosis in lung, skin 
and intestinal mucosa. He was compatible with his mother at all HLA class II loci and 
by a mixed leukocyte reaction his CD4+ and CD8+ cells responded by a two-fold 
increase when activated to his mother’s cells (216). 
 
2.7 OTHER SOURCES OF MICROCHIMERISM 
 
Additional sources of microchimerism than the actual known pregnancy and a 
woman’s born children could make the interpretation of results hard. Male 
microchimerism has been detected in women who have never given born to a son (217-
219). Since it is known that FMc may follow spontaneous or induced abortion it is 
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feasible that male microchimerism in a woman could stem from an early, unnoticed 
miscarriage (220). However, the findings of male cells in female children and fetuses 
cannot be explained by this (221). Furthermore, female UCB samples compromised 
HY-specific cytotoxic T cells from neonates both with older brothers and without 
which made the authors speculate in that male microchimerism from the mothers’ older 
brothers or a miscarriage of the mother could induce an anti HY-response (222). Thus, 
the findings may be a result of a “trans-maternal” flow of male cells. Microchimerism 
in an individual has also been proposed to derive from a vanished twin (223). 
Iatrogenic interventions as blood transfusion organ- and HSC transplantation may also 
give rise to Mc (2-4). 
Whether sexual intercourse will be followed by male Mc is currently unknown. 
However, the findings that expansion of T regs is stimulated at the encounter with 
seminal fluid might indicate that (104). 
The findings that maternal cells can be transferred from the mother to the offspring by 
nursing stem from mouse studies (224, 225). Consequently it seem to lead to 
additionally induced tolerance to NIMAs in mice (226). Interestingly enough, breast 
milk in humans contains stem cells with multi-lineage properties (227). Whether 
these cells give rise to MMc in the baby is currently not known.     
2.8 ANIMAL MODELS 
 
Rodents are the most frequently used animal model for Mc research. For detection of 
the Y chromosome in PCR, FISH and immunofluorescence assays green fluorescent 
protein (GFP) or bioluminescence-positive male animals are often used (228). 
Congenic or allogenic matings between wild-type females and homozygous GFP 
+/+ males result in the possibility to identify maternal and fetal cells. Maternal cells 
will be GFP- and fetal cells GFP+. When studying MMc in offspring it is required to 
use GFP+/- female mice mated to GFP-/- males. 
 
MMc has appeared to be common both in healthy and in immunodeficient mice (224, 
229). In mice with immunodeficiency they appear earlier in gestation compared to 
healthy mice and are more widely spread (229). Like in humans, the MHC 
compability of mother and pup influences the levels of MMc (230). Although the 
placenta is hemochorial in both rodents and humans, major differences exist between 
their pregnancies. The mouse placenta contains two layers of trophoblasts and one 
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layer of syncytiotrophoblasts whereas the human contains only one layer of 
trophoblasts and has villi resulting in a thicker placenta (231). In mice, trophoblast 
invasion into maternal vasculature is minor, and the exchange of nutrients occurs in 
the labyrinth area. Decidualization occurs only at the site of implantation. 
Pregnancy differs between the two species also in immunological and endocrinological 
manners (231). Taken together these differences, cautions must be made when 
comparing MMc and its consequences in humans and in rodents. 
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3 AIMS 
 
The overall aim of this thesis was to study the phenomenon of MMc and explore its 
physiogical role and kinetics in normal pregnancy as well as investigate the possible 
persistence of MMc during childhood and adult life, especially in connection with 
development of autoimmune disease, like SLE. 
 
The specific aims were: 
 
1. To investigate the occurrence of maternal cells of different cellular subsets in 
tissues of 2nd trimester fetuses. (Paper I) 
2. To investigate the occurrence of maternal cells in healthy children’s tonsils, 
adenoid and blood. (Paper II) 
3. To investigate the association between SLE in adults and MMc in peripheral 
blood. (Paper III) 
4. To investigate the occurrence maternal cells of different cellular subsets in cord 
blood of term infants. (Paper IV) 
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4 SUBJECTS AND METHODS 
 
4.1 SUBJECTS 
 
Paper I 
Tissues were sampled from five 2nd trimester fetuses that were aborted on request 
(gestational weeks 14-17). An additional five cases of termination of pregnancy, 
aborted due to trisomy 21 and/ or malformations, were included (gestational weeks 
15-18). Finally, a stillbirth from the 27th gestational week was investigated. Seven 
fetuses were male and four were female. 
Gestational age was determined by measurements of the biparietal diameter of the 
fetus by abdominal ultrasound prior to the abortion. Gestational age was expressed in 
completed weeks. The termination of the pregnancies was performed by oral 
administration of mifeprostone 600 mg on day 1 and misoprostol  800 mg vaginally 
followed by 400 mg misoprostol orally every third hour until the abortion was 
completed on day 3. The intrauterine fetal death was induced with 600 mg 
mifeprostone followed by vaginal administration of gemeprost the following day. 
The bodies of the fetuses were accurately washed and the tissues were collected at 
autopsy and placed in sterile NaCl. Peripheral blood was drawn from the mothers. 
 
Paper II 
Tissue samples from the tonsils and/ or the adenoid of 20 children undergoing 
tonsillectomy and/or adenoidectomy due to recurrent tonsillitis and/ or respiratory 
obstruction were collected prospectively. A questionnaire about the health conditions 
of the mother and the child was answered by the mother. Details regarding the 
questionnaire are provided in Discussion. 
The children were between two and 15 years of age (mean age 5,2) and consisted of 
14 boys and six girls. 
Peripheral blood was collected from the mothers and the children. The tonsils and 
adenoids were removed by curettage under general anesthesia and dissected 
immediately after the surgery under sterile conditions. Four central parts of the tonsil 
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and two central parts from the adenoid, each measuring approximately 5 × 5 × 5 mm, 
were collected for analysis in order to avoid contamination of blood, epithelial cells 
and inflammatory exudates on the surface. No histopathological examination of the 
tissues was performed. 
 Paper III 
The study subjects originated from a large genetic study at the Department of 
Rheumatology, Karolinska University Hospital that was conducted during the period 
1995-1998. In the original study, 208 patients and their first-degree relatives were 
included. All patients fulfilled at least four of the 1982 revised American College of 
Rheumatology Criteria for classification of SLE. Information about the patients was 
collected from medical records, by review of medical history and examination of the 
patients according to a structured protocol by a rheumatologist. Systemic Lupus 
Activity Measure (SLAM) and Systemic Lupus International Collaborating Clinics 
(SLICC) damage index were used to measure SLE disease activity and organ damage 
respectively. First degree relatives filled in a questionnaire about their health. Blood 
samples were drawn for genetic and other analysis from patients and their relatives 
and stored at -70˚ C. 
Thirty-two patients of the originally 208 were recruited to our study (30 women and 
two men), with a mean age of 32 (range 18-52). The female patients were selected 
due to the fact that they had reported themselves as nulligravida in the questionnaire. 
The healthy control group was consisted of 17 brothers of the patients. Even those 
men whose sisters were excluded from the study because of past pregnancy were 
included. Additionally, 12 healthy, unrelated males were recruited to the control 
group. The mean age of the 29 controls was 31 (range 10-54). No difference in age 
between the patients and controls appeared (p-value=0.8). 
Paper IV 
UCB samples, included in the study originated from 44 normal, term pregnancies. 
They derived from 24 vaginal deliveries, 18 elective and two emergency caesarian 
sections. The donors, 23 girls and 21 boys, were all born healthy. The characteristics 
of patients and UCB samples are shown in Table I.  
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Table I 
Patient and umbilical cord blood characteristics. 
  Whole group Vaginal C/S 
Age mothers (years) 30 (±4) 28 (±4) 31 (±4) 
Gestational age (weeks+days) 39+1 (±1w+1d) 39+3 (±1w+2 d) 38+6 (±1 w) 
Weight baby (grams) 3394 (±302) 3427 (±324) 3355 (±276) 
Clamping time (seconds) 52 (±25) 71 (±20) 30 (±4) 
WCB (108/L) 78 (±19) 81 (±22) 75 (±16) 
Total amount WCB (108) 6.7(±1,7) 6.9 (±1.5) 6.7 (±1.8) 
C/S= caesarian section WCB= white cell blood count  
The UCB samples were collected with the purpose to be altruistically donated to 
Sweden’s national UCB bank but the units used in the study included a too low total 
white cell count for banking and were therefore donated to research. 
The sampling of UCB is standardized and is performed as sterile as possibly; the 
umbilical cord is washed at least three times with chlorhexidine, the umbilical cord 
vein punctured and the UCB collected into a UCB collection bag by gravitation 
before the placenta is delivered. In vaginal deliveries the cord is clamped and cut after 
approximately one minute and in caesarian sections after 30 seconds. Specific 
clamping time is recorded with a timer for each collection.    
Peripheral blood was collected from the mothers at the time of delivery. 
4.2 METHODS 
 
4.2.1 Disintegration of tissues. Paper I and II 
 
The fetal, tonsil and adenoid tissues were disintegrated by passage through a 100-µm 
nylon mesh to form a single cell suspension and diluted in NaCl. 
4.2.2 Cell separation. Paper I and IV 
 
To evaluate lineage-specific chimerism in fetal tissues (paper I) and in UBC (paper IV) 
separations of cells were made by means of immunomagnetic beads according to the 
manufacturer’s instructions (Dynal Biotech, Oslo, Norway). In fetal tissues separations 
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of CD3+, CD19+, CD34+ and CD45+ were derived from various organs. In UCB 
samples the separation included  CD3+, CD19+, CD33+, CD34+ and CD56+.  
 
4.2.3 DNA extraction. Paper I, II, III and IV 
 
In paper I and II, DNA was extracted from tissues and whole blood using Quiagen Mini 
Kit (Quiagen, Hilden, Germany). The method includes enzymatic lysation of the cells 
by proteinase K. The tissue samples were digested at 37˚C overnight on a shaker 
whereas the blood was digested at 60˚C for 10 minutes. To purify and to concentrate 
the DNA, a silica-membrane-based nucleic acid purification, procedure was used. The 
same method was also used to extract and purify the samples from the unrelated 
controls in paper III. In paper IV, the extraction of DNA was automatized in an EZ1 
machine using magnetic silica particles (Quiagen, Hilden, Germany). Genomic DNA 
concentrations were measured using NanoDrop (Thermo Scientific, Delaware, USA) 
and diluted to required concentrations. 
 
4.2.4 HLA typing. Paper I and II 
 
In paper I, mothers and fetuses were HLA typed with PCR-SSP (OlerupSSP, 
Stockholm, Sweden) with the intention to identify a NIMA in the fetus that could be 
targeted in the PCR assays in order to detect MMc in the fetal tissues. In paper II, the 
purpose was to examine if any correlation between the presence of MMc and the 
various combinations of mother/ child HLA classes was found. The PCR assays in this 
paper were based on polymorphism in biallelic systems (see 6.1). 
In paper I, HLA typing was performed by PCR amplification with HLA-DR. If the 
sequence difference was not large enough between mother and fetus, typing for HLA-A 
and HLA-B was performed. Primers specific for maternal HLA sequences were 
designed for each fetus- mother pair and tested for specificity and sensitivity (see 
4.2.5). 
In paper II, HLA-A,-B and DRB1 polymorphism were determined using standard PCR-
based methods (LabType, One Lambda, Inc, CA) including sequence-specific 
oligonucleotide probes (PCR-SSOP) using xMAP technology (Luminex System, 
Luminex Corporation, Austin, TX). 
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4.2.5 Semi-quantitative PCR. Paper I 
 
PCR amplifications were performed with maternal-specific primers in a volume of 50 L 
containing 1g genomic DNA, 0.5M of each primer, 200M of each dNTP (Perkin-
Elmer, Branchburg, CA), 1 PCR buffer (1.5 mM MgCl, 50 mM Mg, 10 mM KCl, 
0.001% gelatin), 5% glycerol, 5g cresol red, and 1.5 U AmpliTaq polymerase (Perkin-
Elmer). After an initial 3 minute hot-start/ denaturation step at 94°C, 40 PCR 
amplification cycles were carried out in a PTC-200 thermal cycler (MJ Research, 
Watertown, CA). The positive control contained maternal DNA and the negative 
control distilled H2O. The PCR products were separated on a ready-to-use 
polyacrylamide gel electrophoresis gel for 1 hour and visualized by an automated silver 
staining method. The band patterns were then analyzed under visible light. We 
considered the analyzed organs positive for maternal cells when we were able to 
identify a band pattern of maternal alleles on the PCR gel either in whole tissue or cell-
separated fractions. Figure 6. 
 
 
Figure 6. Example of PCR gel from a semi-quantitative assay. 
 
Serial dilution experiments were performed to establish the sensitivity of the PCR 
amplification. Decreasing amounts of maternal DNA were mixed with DNA from a 
third individual, with the same HLA type as the fetus to give fixed amounts of 1g DNA 
with final concentrations of maternal DNA of 1%, 0.1%, 0.01%, and 0.001%. The 
resulting DNA mixture was subsequently amplified using the maternal-specific primers 
and analyzed as described in previous text. A semiquantitative analysis was performed 
in which the intensity of the sample bands on the gel was compared with the 10-fold 
dilution series. In conclusion; the sensitivity was estimated to 1/ 100.000. 
 
4.2.6 Quantitative Real-Time PCR (QRT-PCR). Paper II, III and IV 
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In paper II, III and IV, QRT- PCR was used based on single-nucleotide polymorphism 
(SNP) and insertion/ deletion polymorphism (INDEL) referred to as biallelic genetic 
systems. Initially, screening of the mother and the offspring was performed by using a 
small amount of DNA (10 ng) in a PCR assay. The allelic markers used were: S01a, 
S02, S03, S04a, S05b, S07a, S07b, S08b, ID1, ID2, ID4 and ID7. If no differences 
were found the pair was screened for additional 10 markers (S01b, S04b, S06, S09b, 
S010a, S011b, ID9, ID10, ID11 and ID12). For each biallelic system, one of the 
primers was from the polymorphic region to specifically amplify each allele, whereas 
the second primer and the probe were common to both alleles. An allele was considered 
informative when it was positive for maternal DNA and negative for the child’s DNA. 
Detection and quantification with one to three markers were performed with the 7500 
Sequence Detection System (Applied Biosystems, Foster City, CA), using TaqMan 
technology. The amount of amplifiable DNA in each sample was assessed by parallel 
amplification of the reference gene glyceraldehyde phosphate dehydrogenase 
(GAPDH). All the samples were run in duplicate, and both maternal and patient/ 
control DNA samples were included in each run. Relative quantification of recipient 
DNA was calculated according to the ∆∆Ct method (Applied Biosystems, user bulletin 
2), using GAPDH as a reference gene and the maternal DNA sample as a calibrator. 
The amount of DNA used in the studies varied between 150– 500 ng. The specificity 
and sensitivity of the QRT-PCR method was determined for all markers included in this 
study using artificial DNA mixtures and varying DNA amounts. With 150-450 ng of 
DNA, a sensitivity of 0.01% was reached for most markers and no false positive results 
was found using 40 cycles of PCR amplification. Figure 7. 
 
Figure 7. Example of a QRT-PCR assay 
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4.3 STATISTICAL METHODS 
 
Paper III. Statistical analyses for age differences between patients and controls were 
conducted with student’s t-test. Chi-square test was performed to analyze differences 
in MMc frequency between the two groups. Statistical analysis was performed using 
Statistica 10, StatSoft, Tulsa, USA. 
 
4.4 ETHICAL CONSIDERATIONS 
 
Paper I: The study was approved by the Etics Committee at Huddinge University 
Hospital (Dnr 129/01) 
Paper II: This study was approved by the Ethics Committee at Karolinska University 
Hospital (Dnr 2008/3:3). Institutional Review Board consent was obtained from all 
patients 
Paper III: The Regional Ethics Committee, Stockholm, Sweden (2012/203–31/2) 
approved the study. The Local Ethics Committee at Karolinska University Hospital 
approved the original study in 1995 (Dnr 95–178 (950616)). Written informed consent 
was obtained from all participants. The caretakers of minors gave written consent on 
their behalf. The signed consent forms are stored with the research file. 
Paper IV: The study was approved by the Regional Ethics Committee, Stockholm, 
Sweden (Dnr 2012/480-31/3). Informed written consent was obtained from all 
participants. 
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5 RESULTS 
 
Paper I. Maternal cells are widely distributed in 2nd trimester fetal tissues. 
Maternal cells were found in seven of 11 fetuses. The fetuses were between gestational 
week 14 and 18 and consisted of four males and three females. MMc was detected in 
all organs investigated (lung, thymus, kidney, heart, liver, spleen, brain, gonads). In 
four fetuses, no MMc was detected in any tissue. No differences were detected between 
abnormal or normal fetuses; three of the five abnormal and four of the five normal 
fetuses harbored MMc and. The stillborn fetus was negative for MMc.  
No specific organ appeared more positive for maternal cells than others but there was a 
tendency that cases with stronger positivity showed uniformly strong positivity in most 
fetal tissues. Levels of maternal cells ranged from 1/ 100- 1/100.000 
(semiquantitatively estimated). Five of the seven cases subjected to analysis of different 
cellular subsets of maternal cells in fetal tissues presented with maternal mature 
immunological cells (CD3+, CD19+, CD45+) as well as cells of progenitor type 
(CD34+). The results are shown in Table II. 
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Table II 
Distribution of maternal alleles in fetal tissues after cell separation. 
Tissue Antigen Case 1  Case 3  Case 4  Case 5  Case 8  Case 9 Case 10 
Lung CD3       +      ++       - NT       - NT       - 
Lung CD19       -      ++       - NT       -       -       - 
Lung CD34       -      ++       -    ++++       -       -       - 
Lung CD45       -     +++       -    ++++       -       -       - 
Thymus CD3 NT       -       +    ++++       -       -       - 
Thymus CD19 NT       +       -    ++++       -       -       - 
Thymus CD34       -       -       -    ++++       - NT       - 
Thymus CD45 NT     +++       +    ++++       - NT       - 
Liver CD3       -      ++       -     +++       - NT       - 
Liver CD19       -      ++       -     +++       -       -       - 
Liver CD34       -     +++       -     +++       - NT       - 
Liver CD45       -     +++       -    ++++       -       -       - 
Spleen CD3 NT      ++       +    ++++       - NT       + 
Spleen CD19 NT       -       -    ++++       -       -       - 
Spleen CD34       +       +       -    ++++       - NT       - 
Spleen CD45 NT     +++       +    ++++       -       -       - 
Kidney CD34       -       -       -    ++++ NT       -       - 
Heart CD34       -       -       -    ++++ NT       -       - 
Adrenal gland CD34       -       +       - NT NT       -       - 
Pancreas CD34 NT NT       + NT NT NT       - 
Ovary CD34 NT NT NT NT NT NT NT 
Testis CD34 NT       -       -    ++++ NT       -       + 
Brain CD34 NT      ++ NT NT NT NT       + 
"-": no maternal DNA detected, "+": maternal cells detected at a level of 10-4-10-5, "++": 10-3-10-4, 
"+++": 10-2-10-3, "++++":>10-2. "NT" = not tested 
 
Paper II. Maternal cells are common in children’s tonsils and/ or adenoid. 
MMc was present in four of 20 (20%) children’s tonsils or adenoids. The age of the 
children (two girls and two boys) ranged from four to six years. Two of them were 
positive in all fractions of tonsils (four fractions) and adenoid (two fractions) tested 
respectively, one was positive in three of the four tonsil fractions and one child was 
only positive in one of the four tonsil fractions. All children positive in tissues were 
also positive in blood. Levels of maternal cells ranged from 2 x10-2 to 7.1 x10-5 in 
tissues and from 1 x10-3 to 7 x10-3 in peripheral blood. No noticeable correlation 
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between the presence of MMc in the tissues and the various combinations of HLA 
relationship of mother and child was found. 
Paper III. There is no correlation between MMc and SLE in adults. 
MMc was detected in peripheral blood of two (patient 153 and patient 156) of 32 
patients with SLE (6%) and in one of 29 healthy controls (3%) (P-value = 0.65). The 
phenotype of the patients did not differ from the negative ones regarding phenotype or 
age. The characteristics of the two positive patients in relation to all study subjects are 
shown in Table III. 
Table III. 
Patient characteristics. 
      Pat 153 Pat 156 
Age at inclusion 31,7 ± 10,4 Range 18,3-51,3 43 38 
Gender, female 30/32 (94%)   + + 
Age at SLE onset 23.4  ± 7.5   23 36 
Discoid lupus 3/32 (9%)   0 0 
Butterfly erythema* 19/32 (59%)   1 1 
Photosensitivity* 18/32 (56%)   1 1 
Oral ulcers* 9/32 (28%)   0 0 
Arthritis* 26 /32 (81%)   1 1 
Serositis* 5/32 (16%)   0 0 
Nephritis* 17/32 (53%)   0 0 
Haematology* 26/32 (81%)   0 0 
Neurology* 3/32 (9%)   0 0 
Anti nuclear antibodies* 31/32 (97%)   1 1 
Immunology* 25/32 (78%)   1 1 
Number of ACR criteria* Median 6 Range 4-8 6 6 
SLAM Median 6 Range 1-15 5 7 
SLICC Damage index Median 0 Range 0-5 0 0 
APS syndrom 3/32 (9%)   0 0 
*Manifestations are defined according to American College of Rheumatology´s  1982 revised criteria for SLE 
(232), SLAM = Systemic Lupus Activity Measure , a validated measure of disease activity (233),  SLICC = 
Systemic Lupus International Collaborating Clinics damage index, a validated cumulative organ damage (234), 
APS =antiphospholid syndrome was diagnosed according to the Sydney criteria(235) 
 
The concentration of maternal cells was 0,006% and 0,002% in the two patients, 
respectively. In the healthy male control, the maternal cells constituted 0.004%. At the 
follow up in present time, all three individuals tested negative for MMc, 16 years after 
the first draw date. 
 40 
 
Paper IV. Maternal CD 34+ and CD 56+ cells are present in UCB. The 
frequency of MMc in cord blood may depend on clamping time and/ or mode of 
delivery.  
Five out of 44 (11%) UCB samples were positive for MMc (Table IV). 
 
Table IV 
Summary of MMc-positive UCB samples. 
Patient no Mode of 
delivery 
Gestational 
age             
(weeks+days) 
Parity Previous 
fetal loss 
Clamping 
time         
(seconds) 
Gender child WCB      
(10^8/L) 
% MMc 
in CD34 
% MMc 
in CD56 
% MMc 
in total 
DNA 
5 El C/S 38+1 0 0 30 B 84 0 0 0.01 
6 El C/S 38+6 1 1 30 B 100 1.5 0.3 0.2 
8 El C/S 39+0 0 1 30 B 61 0.5 0 0 
17 El C/S 38+4 2 1 35 B 45 0 0 0.1 
37 vaginal 38+5 1 0 60 G 95 0 0.07 0 
El C/S = Elective caesarian section B = boy G = girl WBC = white cell blood count 
Two were positive only in the total DNA fraction (case 5 and 17), one in the CD34+ 
fraction (case 8), one in the CD56+ fraction (case 37) and one in the fractions of total 
DNA, CD34+ and CD56+ (case 6). The estimated concentration of maternal DNA 
ranged from 0.01% to 1.5%.  No sample was positive for maternal cells in the CD3+, 
CD19+ or CD45+ fractions. All five positive samples were from babies with healthy 
mothers of whom four were delivered by elective caesarian section (80%) and one 
vaginally. In the group of negative samples 16 of 39 (41%) mothers were delivered 
by caesarian. The mean clamping time in the positive group was 37 ±13 seconds 
compared to 54 ±26 seconds in the negative group. Four of the five (80%) mothers of 
the positive babies had been pregnant before (54% in the negative group). Two of 
them (40%) had had a previous delivery (38% in the negative group), two (20%) had 
experienced at least one fetal loss (miscarriage or elective abortion) but no previous 
delivery (negative group 38%) and one (20%) had experienced at least one fetal loss 
and had given birth before (20% in the negative group). The mean white cell blood 
count per liter in the UCB samples of the positive group was 77 ±23 and in the 
negative group, 80 ±21. 
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6 DISCUSSION 
 
6.1 METHODOLOGICAL CONSIDERATIONS 
 
Studying MMc requires exceptionally sensitive methods due to the limited number of 
foreign (maternal) cells in the sample of the offspring. With too high sensitivity, the 
risk of false positivity, i.e. less specificity, follows. In our work on MMc we have used 
two different kinds of PCR; conventional PCR with subsequent separation of the PCR 
products with electrophoresis followed by visualization by an automated silver staining 
method (paper I) and Quantitative Real-Time PCR (QRT-PCR) (paper II, III and IV). 
One of the advantages with QRT-PCR compared to conventional PCR is the lower risk 
of contamination; the amplified sample is not taken out from the tube for further 
analysis. It is also less time consuming because the detection step is included in the 
PCR reaction and post PCR analysis with electrophoresis or blotting is not necessary. 
The detection of the amplified PCR product is rendered by means of fluorescent 
molecules, in our assays a TaqMan-probe. The fluorescent signal that is emitted is 
proportional to the amount of amplified DNA in the PCR reaction, resulting in 
quantification of the amount of DNA in the original sample. The conventional PCR 
method is only semiquantitative. The intensity of the sample bands was in paper I 
compared with a 10-fold dilution series with fixed concentrations of maternal DNA of 
1%, 0.1%, 0.01%, and 0.001%  
The sensitivity and specificity of the PCR method is, among other things, dependent on 
the choice of primers. In paper one, we used primers specific for a non inherited 
maternal HLA allele which are more specific compared to the system of biallelic 
primers (markers) used in paper two, three and four. The biallelic system we used was 
both based on single-nucleotide polymorphism (SNP) and insertion/ deletion 
polymorphism (INDEL).  Due to short polymorphic sequences, only one primer is 
specific in the PCR reaction while the second primer and the TaqMan-probe can bind 
to both maternal and off-spring DNA. Furthermore, in the SNP case, specificity lies in 
only one base in the specific primer. This low specificity increases the risk of false 
positive amplification of negative alleles. The false positive signal can arise during late 
PCR cycles and thereby also limit the sensitivity of detecting the minor allele.  
In the case of HLA, several SNP mismatches are available in the DNA sequence and 
primers can be designed so that both primers are specific in the PCR reaction. This 
increases specificity and sensitivity of the primers. However, the utilization of HLA 
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primers are burdened with much more time consuming work; the mother and offspring 
needs to be HLA typed followed by design of specific primers for the non inherited 
maternal allele and this is not always feasible with a large number of samples. 
The amount of DNA in the sample is also essential to achieve proper sensitivity and 
specificity. The use of HLA specific primers allows higher concentrations due to higher 
specificity whereas biallelic markers work satisfactorily at DNA amounts up to 250 ng. 
Too high DNA amounts may increase the risk of false positive results, due to factors 
explained above. Considering that each cell contains 6 pg of DNA, the use of 250 ng 
DNA will render a sample of 42.000 cells with, theoretically, the ability to detect one 
maternal cell therein. Thus, the sensitivity of our QRT-PCR assays may exceed 0.01. In 
addition, cell separation like performed in paper I and paper VI, also increases the 
sensitivity of the method by removing the inappropriate cell types in the background 
(236).  
The specificity and sensitivity of the QRT-PCR method was determined for markers 
included in our assays using artificial DNA mixtures and varying DNA amounts. The 
PCR assay was validated by mixing DNA from one individual (positive for the three 
markers) in different concentration in a second individual (negative for the markers). 
We detected no false positive results using 500 ng DNA and 40 cycles of PCR 
amplification. 
To strengthen the specificity in the QRT-PCR we used as many different informative 
alleles as possible, usually two, and the samples were always run in duplicates, i.e. four 
wells in total using two markers. We did not consider it positive if not at least two wells 
showed evidence of MMc. This requirement is not always claimed in other studies. 
The use of FISH is very common in MMc research but caution is recommended when 
interpreting results due to low specificity (237). The approach is to use probes directed 
to X and Y chromosomes which limits the detection to female cells in male tissue. The 
greatest advantage lies within the in situ method itself. It enables the visualization of 
maternal cells in a tissue and combined with phenotypic markers that are tested 
simultaneously with the XX/ XY probes make possible the characterization of maternal 
cells within the tissue. However, the risk of false positive results in determination of 
those rare cells is high due to misinterpretation of cells going through mitosis and 
overlapping or fusion with host cells. Verification by the microchimeric cells in a FISH 
assay could be performed by laser microdissection and subsequent laser-catapulting 
followed by PCR (238). 
 
 43 
 
6.2 FINDINGS AND INTERPRETATIONS 
 
6.2.1 Ontogeny of MMc. Paper I, II and IV 
 
In paper one, two and four we investigated the presence of MMc in fetuses, children’s 
tissues and in cord blood. Still, the ontogeny of MMc is ambiguous. Elucidation of 
questions as “when does the establishment of MMc occur during fetal development and 
in what individuals?”, “where and in what cellular subsets does it persist?” would not 
only contribute to the understanding of how potential allo-autoimmune diseases may 
arise but would also shed new light on mechanisms underlying naturally acquired fetal-
maternal tolerance. This might in turn contribute to the development of alternative 
strategies in HLA- mismatched HSCT, for instance using NIMA- and/ or IPA-matched 
recipient and donor-pairs in UCBT (21, 76).  
 
6.2.1.1 Paper I. MMc in 2nd trimester fetuses. 
 
In paper one, seven of eleven 2nd trimester fetuses showed evidence of MMc in all 
tissues investigated and included all cellular subsets. It would be closest at hand to 
compare our results with MMc in tissues of newborns and infants. Stevens et al. found, 
in contrast to us, few maternal hematopoietic cells when they investigated seven male 
infants who had died from lupus, infections and fetal hydrops with congenital 
anomalies (127). Similar to our study, maternal cells were widely spread and found in 
all tissues examined, including liver, pancreas, lung, bladder, skin and spleen. 
Interestingly enough, in contrast to the rare CD45+ and CD3+ cellular subsets, the 
frequency of differentiated tissue-specific maternal cells was high; in liver up to 42% of 
the maternal cells stained positive for cytokeratin and was found in six of seven infants, 
in kidney all maternal cells expressed cytokeratin and had the morphology of renal 
tubular cells and in pancreas, among islet β cells, up to 1.9% were maternal. MMc was 
not found in inflammatory areas but in normal organs. This is in line with Nelson et al 
who detected islet β cells of maternal origin in children with TD1 but infrequent CD 
45+ cells (188). Since we did not (and no others either) examine differentiated tissue-
specific maternal cells in the fetuses, it is not possible to say if the differentiation takes 
place already in fetal life or after birth. Speculations could be made that the maternal 
cells may develop towards different directions as the immune system develops in the 
host. MMc in tissues of older children is common, both in healthy and diseased, but 
few studies have evaluated if the cells are tissue-specific.  
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All fetuses in our study that were positive of MMc and then subjected to analysis of 
cellular subsets presented with CD 34+, a marker for HSC, in different organs. HSC are 
multipotent cells that differentiate into all kinds of blood cells and simultaneously 
replicate themselves to maintain self-renewal (239). Furthermore, recent reports have 
demonstrated that HSC may be even more plastic. The findings that HSCs are capable 
of differentiating into cell types of unrelated tissues originate from both mouse and 
human clinical studies where donor HSC cells have been found to give rise to 
endothelial precursors, neuronal brain cells, hepatic cells, skeletal muscle and cardiac 
muscle cells (240-244). In humans, donor specific marrow cell-derived epithelial and 
endothelial cells have also been found in the skin of the recipient and in endovascular 
epithelium (245, 246). These reports suggest that HSCs are able to transdifferentiate 
across the embryonic germ layer barrier, for example differentiation of HSCs into 
neural cells (mesoderm to ectoderm). A transfer of HSCs into muscle, however, would 
be within the same germ layer, the mesoderm. If the microchimeric, maternal CD34+ is 
comparable in its feature with the transplanted adult HSC, it could be interpreted that 
maternal CD 34+ cells in the fetus may give rise to tissue-specific cells after birth. 
However, other types of maternal stem cells could also be the origin. It is unknown 
whether MMc could be considered as benign and part of normal tissue generation in the 
fetus and infant but be recognized by the host as foreign later in life. 
In paper I we did not conduct an in situ analysis. This is a limitation due to the fact that 
we cannot say for certain that the maternal cells were incorporated in the fetal tissues or 
if they were circulating freely.  
 
Where do the residing transferred maternal cells hide? Do they home to bone-marrow 
as other stem cells? No previous study has investigated MMc in bone marrow. An 
interesting study by Gammill et al. investigated the presence of MMc in pregnant 
women longitudinally, that is if the soon-to-be grandmother’s DNA was detectable in 
the soon-to-be mother (247). Twenty-seven women with normal pregnancies and 20 
women who developed preeclampsia were included. In healthy pregnancies, the 
prevalence was 0% early in gestation but increased with every trimester, to be 
detectable in 16% in 2nd trimester and 29% in 3rd trimester. Post partum the prevalence 
was 14%. The concentration of MMc also increased through pregnancy. In the 
pregnancies complicated by preeclampsia, none had detectable MMc at any time. This 
finding may reflect that different immunological conditions may have an effect on the 
detectability of MMc. The authors speculated that the increase in MMc in peripheral 
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blood may be a consequence of a generalized stem cell mobilization that occurs in 
healthy pregnancy which in turn could be triggered by the load of fetal antigenic 
material seen in the third trimester and that function could be impaired in preeclamptic 
patients. A future study could be to analyze MMc in bone marrow of prospect HSCT 
donors or to evaluate if maternal cells can be mobilized to peripheral blood by G-CSF 
(granulocyte colony-stimulating factor) given the donor prior a peripheral HSCT. 
We sought to investigate pregnancies complicated with trisomies due to earlier findings 
of increased fetal-maternal trafficking in pregnancies complicated by aneuploidy (136). 
In paper I, three of four fetuses with trisomy 21 had detectable MMc compared to four 
of seven fetuses without trisomy 21. Of course, the number of subjects is too small to 
draw any definite conclusions from this finding. But the fact that individuals with 
Down’s syndrome has a failing immune system and more often suffer from 
autoimmune disorders, infections and malignancies, makes it interesting to study the 
frequency and levels of MMc in those individuals. It is not only known that T and B 
cells have impaired function in individuals with Down’s syndrome- the thymus is 
smaller and has an abnormal structure, even in newborns. (248). Speculations could be 
made that the semi-allogenic maternal cells pass as not that foreign due to impaired 
immunological function and that the maternal cells later in life could serve as effectors 
or targets in autoimmunity. A small study by Srivitsa et al. examining MMc in different 
tissues of four neonates who had died within the first week after birth, showed the 
highest number of MMc in a neonate with Down’s syndrome (203). 
We did an attempt to analyze MMc in the liver of 1st trimester fetuses that were 
sampled for isolation of different tissue progenitors but we realized that the risk of 
contamination with maternal blood was too high due to the findings of very high levels 
of MMc, to go further with that study. The fetuses were delivered after vacuum 
extraction and though we chose those fetuses that were intact, we could not be sure that 
the maternal blood was properly washed away.  
In conclusion, the cellular subsets in the 2nd trimester fetuses had a mature 
immunological feature that may induce feto maternal tolerance but they could also 
serve as functional cells within the host.  
 
6.2.1.2 Paper II. MMc in children’s tonsils and/ or adenoid 
 
The choice of investigating tonsils and adenoid in children originated in our wish to 
explore MMc in tissues of healthy individuals. In studies examining MMc in different 
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disorders of autoimmunity, usually other patients’ biopsies serve as controls. It can be 
questioned whether such controls reflect the actual MMc status in healthy individuals. 
A critical remark to the use of tonsils and adenoids could be that they were not normal, 
due to the fact that they needed to be ablated and that children with respiratory 
obstruction and/ or recurrent tonsillitis not can be considered as “healthy”. However, 
tissues of healthy individuals are available to a very limited extent. The finding of 
MMc in these specimens could also reflect homing of maternal cells to an 
immunological site. MMc was found in four of 20 children which correlate well to the 
frequency in controls of other studies. The percentage of maternal cells varied between 
0,00075 to 0,02. In our study the children who were found positive in tonsils, were also 
positive in blood. It might be true that tissue and blood MMc frequency correlate well 
in healthy individuals where the maternal cells might appear as “innocent bystanders”, 
but that may not be necessarily true in a diseased individual. An example of this could 
be the report of a patient who died from scleroderma (129). She had no MMc in 
peripheral blood at several sample-takings but was found to harbor high levels in a 
number of organs when she died.  
In paper II we did not make cell separations, so whether the maternal cells are of 
hematopoietic nature or not, we cannot say. Recent research shows evidence that at 
least tonsils might be an extrathymic lymphoid tissue, due to the findings of T cell 
lineage precursors in it (249). But again, the homing of maternal cells in the host is not 
known. Parallels to the findings of differentiated maternal cells in pancreas and heart 
tissue could lead to speculations that maternal cells in the inflamed tonsils and/or 
adenoid were part of a tissue repair process and had migrated there secondarily. This 
would have been possible to confirm or exclude using XX/ XY based FISH 
simultaneously with tissue specific markers for cytokeratin for instance. However, that 
would have limited the study to boys. 
The questionnaire that was answered by the mothers reflects what confounders must 
be considered when analyzing MMc. It also included questions about conditions 
during pregnancy and breast feeding that also could influence MMc. We asked if the 
children had received a blood transfusion, if the child was a twin, if the mother was 
healthy and had had a normal pregnancy and for how long the child was breast-fed. 
First, an earlier blood transfusion could be a confounder even though irradiation of 
the blood in order to eliminate leukocytes routinely is performed, but Mc following 
blood transfusion has been described (2). Mc from a twin could also be interpreted as 
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maternal (223). It has not been investigated if MMc is increased after preeclamptic 
preganancies as it is in FMc but it is not unlikely that MMc is also facilitated due to 
placental dysfunction (138). Brest feeding as an additional source of MMc is 
interesting. In mice it has been shown that maternal cells can be transferred to the pup 
by nursing (224). However, MMc did not persist into adulthood in the absence of 
neonatal exposure through breast feeding (250). In humans, the influence of breast 
feeding on MMc is not investigated.  
6.2.1.3 Paper IV. Cellular subsets of maternal cells in umbilical cord blood 
 
The information on cellular subsets of MMc in cord blood is scarce. Only two previous 
studies have explored this; Wernet et al. found that as much as 10% of all nucleated 
cells in whole blood to be maternal in the one of 16 UCB samples positive for maternal 
cells (193). Five % of the CD3+ cell fraction and 15% of the myelomonocytic cells 
from mononuclear cells were maternal. Of picked BFU-E (erythroid burst-forming 
units) and CFU-GM (colony forming units-granulocyte-macrophage), 15% were 
maternal. That should not be interpreted as microchimerism but rather chimerism and 
consequently questioning of contamination or misinterpretation of maternal cells would 
be proper. Also by FISH, Hall et al. found 7 of 49 UCB samples to be positive for 
MMc. Female CD8+ cells were found in 5 of 39 samples and CD 34+ only in one of 27 
(196) The levels ranged from 0.04% to 1.0%.  
In our study, the frequency of MMc was detected to 11%, somewhat unexpectedly low 
as will be discussed below.  
 
The maternal cellular subsets in cord blood are of importance in two aspects; first of all 
it is of interest in order to understand the ontogeny of MMc. Are maternal cells actually 
present at birth and do they exhibit a character of progenitor lineages with potential to 
engraft and differentiate? The other aspect is what subsets of maternal cells are actually 
co-transmitted as “third party” in UCBT. This is specifically of interest since van Rood 
et al. in two studies showed that the mother of the donor of cord blood seems to 
influence the outcome of the transplantation. The first study showed that when donors 
and recipients were mismatched for NIMAs, the recipient was more likely to have an 
earlier engraftment, less GvHD and decreased rate of relapse of acute myeloid 
leukemia (76). This might be explained by the effect of donor’s T cells (both effectors 
and T regs) with anti-NIMA activity, developed during fetal life. Later, the same group 
showed that if the donor and recipient shared the same IPA, the relapse risk was 
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significantly reduced (hazard ratio=0.35, P <0.001) with a non-significant slight 
increase in GvHD (21). An interpretation could be that maternal T cells might mediate 
this effect. Thus, the microchimeric maternal cells could be the heroes (or heroines) in 
this case, but the real evidence would of course be to demonstrate maternal cells 
exhibiting this effect in the recipient. A consequence of the findings by Van Rood 
would be to HLA-type the mothers of the UCB donors, a procedure that is not yet a 
routine in UCB banking. 
The frequency of MMc in this study (11%) appeared to be somewhat lower than the 
frequency of MMc in children’s tonsils and/ or adenoid (20%). We used the same 
method as in paper II but the samples derived from different ages (and tissues) and the 
kinetics of MMc and natural course is not known. Since the presence of MMc seems to 
depend on HLA compatibility between fetus and mother, the subjects in paper IV might 
have not been compatible by chance. 
Results from previous studies of MMc in cord blood vary greatly (0-100%, mean 14%) 
but they include several different detection methods.  
 
We were interested in two further aspects; whether MMc in UCB is dependent on 
clamping time or mode of delivery. Most of previous studies on MMc in UCB refer to 
“immediate” clamping of the cord, but the practice in Sweden is about to change to 
longer clamping time since infants may benefit from increased hematocrite and higher 
ferritin concentration after birth following clamping time after three minutes. Since this 
will not yield adequate numbers of cells needed in UCBT, a compromise implying 
clamping time of one minute in vaginally deliveries and 30 minutes in caesarian 
sections at the two UCB bank centers (Stockholm and Gothenburg) in Sweden has been 
introduced.  
Actually, we speculated in the planning stage of the study if contractions during labour 
could facilitate the transfer of MMc. The number of positive cases was low but four of 
the five were from deliveries by caesarian sections indicating that this assumption 
might be wrong. However, among the positive cases the clamping time was 
considerably shorter (37 ±13 seconds) compared to the negative group (54 ±26 
seconds) leading to speculations if the clamping time itself affects the transfer of 
maternal cells. If the indirect findings by van Rood that maternal cells in a UCB graft 
could contribute to an improved outcome of UCBT could be directly shown and larger 
studies could confirm that MMc in UCB is enhanced by short clamping time, there 
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would be two advantages with immediate clamping; more cells to the transplant and 
more maternal cells to exhibit the GVL effect.  
The mean concentration of maternal CD34+ and CD56+ cells in paper IV was 1% and 
0.185% respectively. Considering that a typical UCB transplant harbors 3x107nucleated 
cells/ kg recipient body weight and assume that 1% are CD34+ and 20% are CD56+ 
implying that 3x103 maternal CD34+cells and 1.1 x104 CD56+cells /kg are transferred 
with the UCB graft. This amount of cells may be large enough to engraft if co-
transmitted in UCBT (251). 
 
6.2.2 MMc in autoimmunity. Paper III 
 
Indications that MMc could be involved in autoimmune disorders stem from studies of 
SCID that showed that maternal cells persist at high levels and engraft in children with 
this immunodeficiency. Additionally, SCID children develop GvHD to a great extent. 
However, almost all disorders that have been proposed to be associated with MMc (and 
FMc) are basically describing the presence of MMc in peripheral blood or target tissues 
of patients with autoimmune disorders and healthy controls and do not provide 
evidence for the possible function(s) of MMc. 
There are difficulties comparing autoimmunity and GvHD. Autoimmune diseases are a 
heterogeneous group of over 80 disorders that are characterized by pathologic immune 
responses directed at self-tissue and, like in GvHD, the spectra of pathophysiology and 
clinical presentation are broad (252, 253). A further aspect when comparing chimerism 
and consequent GvHD after HSCT and naturally acquired chimerism regards the 
differences in the size of cell populations. After HSCT, the hematopoietic cells of the 
recipient are almost replaced by the donors in contrast to MMc or FMc where they 
constitute less than 0.1%. MMc has been associated with several autoimmune diseases, 
especially in children; JDM, JIIM, neonatal lupus, type 1 diabetes, pityriasis 
lichenoides, biliary atresia (182-190). 
In adults, patients with SSc were found to harbor MMc more often than controls (129). 
All of the above mentioned autoimmune disorders display similarities to GVHD. 
 
6.2.2.1 Paper III. MMc in SLE 
 
The seed to our study arose from Stevens et al.’s findings that bidirectional 
compatibility for DRB1 was associated with SLE when they compared mother/ son 
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compatibility in 30 male SLE patients with 76 healthy males (254). They showed that 
the frequency and concentration of MMc was higher when there was maternal 
compatibility for HLA-DQB1 from the fetal perspective, that is, the mother was DQB1 
homozygous or HLA identical. This, together with the fact that a SLE like disease 
could be evoked in mice by transfusion of homozygous parental lymphocytes into 
heterozygous progeny made Stevens et al. suggest that MMc in SLE patients might be 
elevated. A collaboration with the Rheumatology Department at Karolinska Institutet 
led to our access to stored DNA from SLE patients and their first degree relatives 
(which originated from a large genetic study from the 90s) and gave us the opportunity 
to see if the assumptions of Stevens et al. were true.  
However, we did not find any association; two patients (6%) and one control (3%) 
harbored maternal cells in peripheral blood.  
 
One limitation of our study is that we only investigated MMc in blood and not in 
tissues. This might not reflect a true picture because affected tissues may harbor MMc 
while peripheral blood does not. One patient with SSc in the study by Lambert et al., 
who was negative for MMc in peripheral blood in four occasions, was found to harbor 
MMc in bone marrow prior to her death. After she had died, evaluation of MMc in 
different organs was conducted and it was found in several affected organs. In a study 
of FMc in SLE the presence of chimeric cells in kidney was related to injury (255). A 
patient with SLE was at autopsy found to harbor FMc in every injured organ, but not in 
unaffected tissue (256). This information suggest that future studies of the association 
between microchimeric cells and inflammatory disease should include evaluation of 
Mc in affected organs where microchimeric cells are assumed to be active. In our study 
of MMc and SLE, additional examinations of the occurrence of MMc in for example 
skin, kidneys and synovial fluid would have provided additional information. 
In paper III, the levels of MMc in the two patients (mean 0.004%) and the control 
(0.004%) did not differ. In the literature of Mc in autoimmunity, the association of Mc 
and the disease is sometimes based on an increased frequency of Mc, as in MMc and 
SSc, when other correlation is founded on increased levels of Mc as in FMc and SSc.( 
156,157). 
An advantage with our study was that almost 60% of the control group constituted of 
healthy brothers to the patients. Using siblings as controls reduces genetic and 
environmental influences. 
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When evaluating the presence of maternal cells in an individual, the possibility of 
detecting confounding microchimeric cells of other origin should not be neglected, 
for example from a previous pregnancy i.e. FMc. Not only live births result in FMc. 
Of 120 women without sons, 21% tested positive for male Mc (218). Male Mc 
prevalence was significantly greater in the group of induced abortions (57%) 
compared to those with only daughters (8%), those with spontaneous abortions (22%) 
or those who were nulligravida (10%). Interestingly, the levels of MMc were also 
higher in the group of induced abortions indicating that residing FMc could 
theoretically be misinterpreted as MMc if the fetuses of the abortions share the same 
allele that is considered as the NIMA in a woman. The surprising finding of 10% 
male Mc among the nulligravida might be explained by other possible sources of 
male microchimerism including unrecognized spontaneous abortion or vanished male 
twin. 
In order to minimize the risk of amplifying a polymorphic region of fetal origin in the 
PCR procedure we strictly selected SLE patients who had reported themselves as 
nulligravida. Since this information of the healthy sisters of the patients was not 
available we chose the patients’ brothers and unrelated men as healthy controls. If the 
hypothesis that FMc could be a confounder in detecting MMc in women is true, the 
prevalence and levels of (false) MMc would be higher in parous compared to 
nulliparous women and would consequently increase with number of children. Studies 
that evaluated this specifically are not available but in the report of different cellular 
subsets of MMc in womens peripheral blood, MMc was more prevalent in the parous 
group compared with the nulliparous, 45% (10/22) and 22% (2/9) respectively (201). 
However, the two groups were of limited size. Still, this study had the advantage that 
they had determined the phenotype of the womens children in order to be able to 
exclude them as confounding MMc. Additionally; parous women may have 
experienced fetal losses to a greater extent than nulliparous women (and as a 
consequence have acquired more FMc).    
If residing FMc or MMc in a women could pass over to her current pregnancy in a 
transgenerational manner is not known. Interestingly enough, Dierselhuis et al. found 
male Mc in six of nine UCB samples from girls with older brothers, but none in the 
three samples from firstborn girls (222).  
FMc acquired by the mother from an earlier pregnancy that pass into her current could 
theoretically be misinterpreted as MMc in the current child if the same NIMA is shared 
by the older sibling and the mother. If that hypothesis would be true, the consequence 
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would be that the later birth order a child has, the greater likelihood of MMc (false) 
would be recognized. No studies have addressed this specifically but in the report of 
MMc in cord blood by Scaradavou there were no differences in the frequency of MMc 
in cord blood from babies whose mothers were multigravida (70%) compared to 
primigravida (72%) (198). But in our work, both in paper I and paper IV, there was a 
tendency that the mothers in the positive cases had experienced more pregnancies than 
mothers in the negative cases. A recent study of the association between asthma and 
MMc did not find any correlation of birth order and MMc (257). Accordingly, 
conflicting indirect data of possibly confounding transmaternal flow of FMc in women 
investigated for MMc exists. 
The low prevalence of MMc in paper III could lead to speculations that the 
characteristics of the subjects included (nulligravida women and healthy men) may 
influence the result towards lowe frequency. In adults, men specifically have not been 
subjected to MMc analysis before, and neither have nulligravida women. What if 
previous studies of MMc in women are confounded with FMc? Most studies of 
autoimmune disorders and MMc are conducted in children. Could MMc be more 
prevalent in children, and thus more important as part of certain autoimmunity? Studies 
that investigate the natural course of MMc in healthy individuals could contribute to 
that answer.  
Thus, MMc could be misinterpreted in women with previous pregnancies. The most 
proper way would be to address MMc in males or children with no history of blood 
transfusion. When investigating the incidence of MMc in women, an accurate obstetric 
history and the exclusion of her children carrying the same targeted polymorphism used 
in the analysis, is to be recommended. However, Mc from a vanishing twin is hard to 
rule out as a confounder for MMc.  
In our study of SLE and MMc, we were fortunate to get new blood test from the three 
subjects (two patients and one healthy male) with MMc in the middle of the 90s. All 
three tested negative for MMc 16 years later. The natural course of MMc over time has 
never been investigated. The reason for MMc absence in our follow up could be that 
maternal microchimeric cells age and disappear as other cells even though MMc has 
been detected up to middle age (14). The fact that hematopoietic progenitors are among 
detectable MMc cells make them likely to persist for a long time but to what extent 
they are able to self-renewal is unknown. One can also speculate if immune modulatory 
treatment affects their prescence. For example, MMc disappeared in two patients with 
SSc under cyclophosphamide treatment (258). JDM patients treated with methotrexate 
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harbored MMc less frequently than patients treated with prednisone (259). MMc 
present in autoimmune diseases may also differ during amelioration or flares. The study 
by Gammill et.al. referred to above (6.2.2) showed that the prevalence of MMc in 
healthy pregnant women increased from 0% in the first trimester to 29% during the 
third, suggesting that factors (immunological or due to the increasing maternal blood 
volume) dependent on the pregnancy lead to the mobilization of all sorts of stem cells 
from the bone marrow (247).  
As in many autoimmune diseases, specific HLA alleles are well documented to 
increase susceptibility to SLE. The MHC class II alleles HLA-DRB1*03 and HLA-
DRB1*15 are associated with the disease but just over half of the patients carry the risk 
alleles suggesting other factors to be essential to the development of the disease. In the 
view of HSCT and the importance of histocompatibility in regulating Mc in the 
recipient and subsequent GvHD, the suggestion has been proposed that the HLA 
relationship of host and non-host cells in naturally acquired Mc may be important. This 
matter is already discussed in Introduction. 
In our study of MMc and SLE we did not conduct any HLA analysis of the mother/ 
child pairs. Retrospectively, in the light of the negative association this would however 
not have added any further conclusions. In two of our other studies we conducted HLA 
typing. In the study of 2nd trimester fetuses the typing was done with the purpose of 
finding a non-inherited maternal allele to use in the PCR assay. The typing did not 
result in any particular pattern of compatibility between fetuses and mothers and the 
presence of MMc. In our report of MMc in tonsils and/or adenoids the 20 mother/ child 
pairs were typed for HLA-A, B and DR (results not published) with this intention but 
there were no findings of compatibility from the perspective of the fetus and the 
presence of MMc in this study either. However, the numbers of subjects were 
presumably too small to expect this.  
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7 CONCLUSION AND FURTHER DIRECTIONS 
 
• Maternal cells of lymphoid and myeloid lineages and hematopoietic progenitors 
are widely distributed in 2nd trimester fetuses, including healthy fetuses and 
fetuses with Down’s syndrome. 
 Where do maternal cells home? Investigating bone marrow for the presence 
of MMc compared to peripheral blood in donors of HSC. Do MMc increase 
in peripheral blood in donors treated with G-CSF in order to mobilize stem 
cells before HSCT? 
 Do children and adults with Down’s syndrome harbor MMc to a greater 
extent than healthy individuals? Investigating MMc in peripheral blood 
within different cellular subsets in individuals with Down’s syndrome. 
 Do infants, children and adults with preeclamptic mothers harbor MMc at 
higher levels and frequency compared to individuals born of healthy 
mothers? 
 
• MMc is common in children’s tonsils and/ or adenoids and corresponds to 
levels and frequency in peripheral blood. 
• MMc in cord blood is present and includes CD34+ and CD56+ cellular subsets. 
The transfer of maternal cells may depend on clamping time and/ or mode of 
delivery. 
 Larger studies of cellular subsets of MMc in UCB are needed with defined, 
different clamping times, for example: immediate, after 30 seconds, after 
one minute and after three minutes.  
 Evaluate the presence of MMc and functionality in a recipient after UCBT.  
 
• MMc is not associated with SLE in adults and exhibits low frequency in adult 
nulligravid women with SLE and healthy men. 
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 Future studies of MMc should preferably include children or men 
exclusively to exclude the probability of confounding FMc. If women of 
reproductive age are included, an accurate obstetric history is essential. 
 Analyze the natural course and time kinetics of MMc over time in healthy 
individuals. 
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8 SVENSK SAMMANFATTNING 
 
Begreppet chimär härrör från den grekiska mytologin där det syftar till ett vidunder 
bestående av kroppsdelar från ett lejon, en get och en orm. Inom medicin uppstår 
chimerism som följd av blodtransfusion, benmärgstransplantation eller 
organtransplantation. Chimerism kan beskrivas som närvaron av en annan persons 
DNA eller celler i en kropp. När denna andel av celler är liten (mindre än 1 %) 
benämns tillståndet som mikrochimerism. Den absolut vanligaste orsaken till 
mikrochimerism är graviditet. Länge uppfattades moderkakan som en helt tät barriär 
mellan mamma och foster, men nu är det ett etablerat faktum att det sker en överföring 
av celler i båda riktningarna under en graviditet. Dessa celler kan kvarstå i blod och 
vävnad upp i vuxen ålder. Celler från barnet i mamman benämns fetal mikrochimerism 
och celler från mamman i barnet maternell mikrochimerism. Eftersom kvinnan och 
barnet bara till hälften är lika varandra genetiskt (barnets halva genuppsättning kommer 
från pappan) finner man det anmärkningsvärt att dessa främmande celler inte stöts bort 
eller gör skada. Ett parallellt exempel från medicinen är situationen som kan 
uppkomma efter en benmärgstransplantation där en patients immunförsvar nästan helt 
ersätts av en donators immunceller. De flesta sådana patienter utvecklar en sk graft-
versus-host reaktion , där donatorns celler uppfattar patientens celler som främmande 
och angriper dem i olika vävnader. Angreppen kan ske i många olika organ men 
vanliga exempel är angrepp på hud, slemhinnor och tarm vilket ofta leder till utslag i 
huden och diarré. 
Eftersom många autoimmuna sjukdomar (sjukdomar där kroppens immunförsvar 
uppfattar de egna cellerna som främmande) liknar en graft-versus-host-sjukdom har det 
spekulerats i om mikrochimära celler efter en graviditet kan vara en bidagande faktor?. 
Man har upptäckt en association mellan kvarvarande fetala celler hos kvinnor med tex 
skleroderma som är en typisk autoimmun sjukdom vilken debuterar framförallt i 
kvinnor efter barnafödande ålder. Hos dessa kvinnor har man funnit en högre andel av 
fetala celler i blod och i sjuk vävnad jämfört med friska individer. Celler från mamman 
som återfinns hos hennes barn har sammankopplats med framför allt ganska ovanliga 
autoimmuna barnsjukdomar, men också med en så pass vanlig sjukdom som diabetes.  
Hur förklarar man fyndet av en högre andel mikrochimära celler i samband med vissa 
sjukdomar? 
Teorier som framkastas som förklaring lyder: 
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1. De främmande cellerna verkar som attackceller i mammans eller avkommans 
kropp. 
2. De främmande cellerna är själva målet för mammans eller avkommans egna 
immunologiska celler. 
3. De främmande cellerna förflyttar sig till en redan skadad vävnad och bidrar till 
reparation. 
Således finns det spekulationer om att cellerna är av både ondo och godo. 
Celler från mamman i avkomman, som denna avhandling handlar om, finns i både 
friska och sjuka individer och kan finnas där under lång tid. I en studie hittades celler i 
blod hos en 49- åring som man antog var mammans. En nytta som fostret kan dra av att 
härbärgera en liten del mammaceller är att de hjälper fostret att tolerera sin mamma 
under pågående graviditet. Egentligen borde båda mamma och barn stöta bort varandra 
pga. olika genetiska uppsättningar. Mammaceller i ett foster verkar kunna påverka 
fostret till att producera celler som hämmar andra celler från att attackera mamman. 
Två relativt nya studier som handlar om transplantation av navelsträngsblod till 
patienter med leukemi påvisar att kvarvarande celler från mamman i navelsträngsblod 
kan ha en positiv effekt på utfallet. 
 
Denna avhandling består av fyra arbeten som innefattat följande: 
Arbete 1: Förekomsten av immunologiska mammaceller i olika organ i foster från 
14:e till 18:e  graviditetsveckan. Fem foster var friska och fem hade Down’s syndrom 
och/ eller  missbildningar. Vi undersökte också ett foster som hade dött i livmodern i 
anslutning till 27:e graviditetsveckan. 
Resultat: Vi fann immunologiskt mogna celler från mamman i sju av 11 foster och 
vissa av cellerna var av stamcellskaraktär. Av de friska fostren hade fyra stycken 
mammaceller och bland de sjuka hade tre av fem. Det döda fostret från 27: e veckan 
hade inga mammaceller. Cellerna fanns spridda i samtliga organ vi undersökte, t.ex. i 
lever, brässen, hjärna och lungor. 
Slutsats: Immunologiskt mogna celler i foster är ett vanligt fenomen.  
Arbete 2: Förekomsten av mammaceller i friska barns halsmandlar och näspolyper 
samt i blod.  
Resultat: Fyra av 20 barn hade mammaceller i sina halsmandlar och/ eller polyper. 
Samma barn hade mammaceller i blod också. 
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Slutsats: Mammaceller i friska barns vävnader och blod är vanligt förekommande. 
Detta kan vara viktig information när man undersöker förekomsten av mammaceller 
hos sjuka barn. Oftast jämför man med vävnad från en individ som har en annan 
sjukdom än den aktuella och då kan det bli svårt att tolka resultaten. 
Arbete 3: Finns det någon association mellan sjukdomen systemisk lupus 
erythematousus och mammaceller? Vi undersökte förekomsten av maternell 
mikrochimerism i 32 patienters blod och jämförde dessa med 29 stycken friska män. 
Proverna var tagna i mitten av 90-talet. Vi upprepade analysen bland de som var 
positiva för mammaceller nu 16 år senare.   
Resultat: Bland patienterna hade två stycken mammaceller i blodet och av 
kontrollpersonerna hade en mammaceller. Samtliga tre personer var negativa vid 
uppföljningen. 
Slutsats: Det föreligger ingen association mellan systemisk lupus eryhematousus och 
maternell mikrochimerism i blod. Förekomsten av mammaceller förefaller variera med 
tid. 
Arbete 4: Förekomsten av olika typer av mammaceller i navelsträngsblod hos 44 
stycken fullgångna, friska nyfödda. Vi analyserade om andelen mammaceller kunde 
påverkas av förlossningssätt - kejsarsnitt eller vaginal förlossning - eller av 
avnavlingstiden (tiden mellan barnets födelse och när man stänger av flödet i 
navelsträngen och klipper av den). 
Resultat: Vi fann mammaceller i navelsträngsblodet hos fem av 44 nyfödda. Fyra av 
dessa var förlösta med kejsarsnitt. Mammacellerna var av stamcellskaraktär och ”NK 
celler” (en typ av mördarceller som är viktiga för immunförsvaret). Avnavlingstiden 
var kortare i de fall där man fann mammaceller. 
Slutsats: Mammaceller förekommer i navelsträngsblod hos friska nyfödda. Det är 
möjligt att förlossningssätt och/ eller avnavlingstid påverkar andelen. Fynden kan ha 
relevans vid navelsträngstransplantationer. 
 
 
 
 
 59 
 
9 ACKNOWLEDGEMENTS 
 
A lot of people have contributed to this thesis in different ways. I want to express my 
gratitude to all of you. 
 
Magnus Westgren, my main supervisor, who has the brain of a real scientist and a 
heart that encloses you. Thank you for guiding me in this not always uncomplicated 
field of maternal microchimerism. Thank you for always being generous - with ideas, 
contacts and for being enthusiastic no matter what. But, your taste of working shoes can 
be questioned. 
  
Nikos Papadogiannakis, my co-supervisor and a real friend with a head full of science 
and marathon. By now, I know we have to talk a few minutes about running before we 
can speak of science. Thank you for always welcoming me at F49 and for the space you 
create for me at your messy table. 
  
Mehmet Uzunel, my 2nd co-supervisor, the master of PCR- the methodological 
foundation of this thesis. Thanks for singing to me in the lab and thanks for keeping the 
teasing at a moderate level, when I for dilute the samples with ethanol instead of water. 
 
Marianne van Rooijen, Head of the department of obstetrics and gynecology. Thank 
you for providing me with the opportunity to research. 
 
Gunilla Tegerstedt, Head of the department of gynecology. Thank you for being 
generous and understanding when days and nights were not long enough for the past 
six months. 
 
Carsten Rasmussen, the former Head of the department of gynecology. You are such 
a precious friend and a good doctor. I will always remember the crazy trip to Bari, Italy. 
 
Cecilia Götherström. Thank you for good collaboration. You are an excellent 
immunologist and a superior researcher. 
 
 60 
 
Anna Granath and Elisabeth Svennungsson. Thanks for valuable teamwork in paper 
II and paper III, respectively.  
 
Astrid Börjesson, Ulrica Askelöf and Harjeet Kaur Malhi. Thanks for making a big 
effort collecting cord blood samples for paper IV.  
 
Galina Drozdova. Thank you for helpful administration of everything the past years. 
  
All dear colleagues- nursing assistants, nurses, doctors and midwifes at 
Kvinnokliniken, Huddinge. You make almost every day at work easy and fun. Thank 
you! 
 
Anne Stevens, Associate Professor of rheumatology, Children’s Hospitel, Seattle. 
What luck that I met you! Thank you for being so generous. I really enjoy your 
company and your sense of humor. 
 
Catharina Lundberg and Christina Blixt. Thanks for all the entertainment from the 
time in Nyköping and ahead. 
 
Liv Ahlborg, Helene Haesert de la Motte, Johanna Isaksson, Anna-Sofia Melin, 
Sara Sundén- Cullberg and Fariba Zhaeentan. We matured to decent gynecologists 
together and now we share everything in our formidable network, AGRF (I have forgot 
what it stands for). You are such fun, valuable friends and colleagues. 
  
Eva-Lena Tullbrink Jansson, Johan Lindsjö and Elisabeth Wennergren, my oldest 
play-mates. It is as fun to play with you now as it was when we were eight years old. 
 
Lena Edwall. You are my close friend and have been my supervisor in life and clinics. 
Just recently, my tears have stopped falling after you telling me, 2007, that you were 
moving to Visby. I hope to see more of you from now on. 
  
Kerstin Palm and Elisabet Hjerpe. Thanks for being such fun company and close 
friends. I promise; now there will be more time for mustiga höstgrytor. 
 
 61 
 
Anna Ström, Lotta Ström and Sophia Segrell; for being my extended family for 
many, many years and for introducing me to naked tai chi. “I will always remember 
you in my heart”. 
 
Anette Magnusson with your myriads of daughters; Sophia, Agnes and Vera. Such a 
luck that we ended up in the same group the first term at KI. Thank you for being so 
supportive through the years, for all “Råd and Rön-advices” and fun moments. 
 
Anna Branten, my “schwester” in arms. You remind me that nothing is impossible. 
Thanks for being concerned about me not getting sun-burned and being so open-
minded and playful. Looking forward to future travelling with you, Peter and Fred. 
 
Claes and Kriss , Pontus and Christine and Jesper and Jennie for being the best 
brothers and sisters in-law you can dream of and for rising the best cousins for Lisen; 
Mathias, Fanny, Erica, Filip, Lukas, Hannah and Julia. 
 
Sigbrit Forslin Jonsson, my dear, dear mother. You are such a loving, fun and “katig” 
mother. Thanks for loving me no matter what. I love you right back! 
 
Mattias and Lisen, my miracles in life. Whenever you are not around I long for you. 
Thanks for being so patient and helpful the last months. Mattias, you are such a fun, 
smart and handsome husband (and absent-minded). I am the luckiest woman in the 
world. Lisen, my adorable daughter. Spending life with you is the greatest adventure. I 
am the luckiest mother in the world.  
 
 
 62 
 
10 REFERENCES 
 
1. Homer, Iliad 6.179–182 
2. Reed W, Lee TH, Norris PJ, Utter GH, Busch MP. Transfusion-associated microchimerism: a 
new complication of blood transfusions in severely injured patients. Seminars in Hematology. 
2007;44:24–31. 
3. Starzl TE, Demetris AJ, Murase N, Ildstad S, Ricordi C, Trucco M. Cell migration, chimerism, 
and graft acceptance. Lancet 1992; 339:1579–82. 
4. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C. Quantitative assessment of 
hematopoietic chimerism after bone marrow transplantation by real-time quantitative 
polymerase chain reaction. Blood 2002;99:4618–25. 
5. Lo YM, Lau TK, Chan LY, Leung TN, Chang AM. Quantitative analysis of the bidirectional 
fetomaternal transfer of nucleated cells and plasma DNA. Clin Chem. 2000;46:1301-9 
6. Papadogiannakis N. Traffic of leukocytes through the materno-fetal placental interface and its 
possible consequences Curr Top Microbiol Immunol. 1997;222:141–157 
7. Medawar PB: Some Immunological and Endcrinological Problems Raised by Evolution of 
Viviparity in Vertebrates. (ed) by Symposia of the Society for Experimental Biology. London, 
UK, Syndics of the Cambridge University Press, 1953. 
8. Schmorl G. Pathologisch-anatomische Untersuchungen über Puerperal-Eklampsie. Verlag FCW 
Vogel, Leipzig;1893. 
9. Williams. Obstetrics: A textbook for the use of students and practitioners. Appleton Press; New 
York: 1907. 
10. Douglas GW, Thomas L, Carr M, Cullen NM, Morris R. Trophoblasts in circulating blood 
during pregnancy. Am J Obstet Gynecol. 1959;78:960 73.  
11. Walknowska J, Conte FA, Grumbach MM. Practical and theoretical implications of fetal 
maternal lymphocyte transfer. Lancet 1969;1:1119 22. 
12. Desair G, Creger WP. Maternofetal passage of leukocytes and platelets in man. Blood 
1963;21:665-73. 
13. Zarou DM, Lichtman HC, Hellman LM. The transmission of chromium-51 tagged maternal 
erythrocytes from mother to fetus. Am J Obstet Gynecol. 1964;88:565-71. 
14. Maloney S, Smith A, Furst DE, Myerson D, Rupert K, Evans PC, et al. Microchimerism of 
maternal origin persists into adult life. J Clin Invest. 1999;104:41-7. 
15. Bianchi DW, Zickwolf GK, Weil GJ, Sylvester S, DeMaria MA. Male fetal progenitor cells 
persist in maternal blood for as long as 27 years postpartum. Proc Natl Acad Sci USA 1996; 
93:705–8.  
16. Billingham RE, Medawar PB. Desensitization to skin homografts by injections of donor skin 
extracts. Ann Surg. 1953;137:444-9.   
17. Mold JE, Michaëlsson J, Burt TD, Muench MO, Beckerman KP, Busch MP, et al. Maternal 
alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science 
2008; 322:1562–5.  
18. Van Rood JJ, Eeenisse JG, Van Leeuwen A. Leucocyte antibodies in sera from pregnant 
women. Nature. 1958;181:1735-6. 
19. James E, Chai JG, Dewchand H, Macchiarulo E, Dazzi F, Simpson E. Multiparity induces 
priming to male-specific minor histocompatibility antigen, HY, in mice and humans. Blood  
2003;102:388-93.  
 63 
 
20. Tafuri A, Alferink J, Möller P, H mmerling GJ, Arnold B. T cell awareness of paternal 
alloantigens during pregnancy. Science 1995;270:630–3. 
21. van Rood JJ, Scaradavou A, Stevens CE. Indirect evidence that maternal microchimerism in 
cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. Proc Natl 
Acad Sci U S A 2012;109:2509-14. 
22. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the 
fetus. Nat Immunol 2004;5:266–71. 
23. Nelson JL. Maternal-fetal immunology and autoimmune disease: is some autoimmune disease 
auto-alloimmune or allo-autoimmune? Arthritis Rheum. 1996;39:191-4.  
24. Harris LK, Smith SD, Keogh RJ, Jones RL, Baker PN, Knöfler M, et al. Trophoblast- and 
vascular smooth muscle cell-derived MMP-12 mediates elastolysis during uterine spiral artery 
remodeling. Am J Pathol. 2010;177:2103-15.  
25. Cartwright JE, Fraser R, Leslie K, Wallace AE, James JL. Remodelling at the maternal-fetal 
interface: relevance to human pregnancy disorders. Reproduction 2010;140:803-13.  
26. Dawe GS, Tan XW, Xiao ZC. Cell migration from baby to mother. Cell Adh Migr. 2007;1:19-
27.  
27. Kline BS. Microscopic observations of the placental barrier in transplacental erythrocytotoxic 
anemia (erythroblastosis fetalis) and in normal pregnancy. Am J Obstet Gynecol. 1948;56:226-
37. 
28. Devi B, Jennison RF, Langley FA. Significance of placental pathology in transplacental 
haemorrhage. J Clin Pathol. 1968;21:322–31. 
29. Jauniaux E, Hustin J. Histological examination of first trimester spontaneous abortions: The 
impact of materno-embryonic interface features. Histopathology 1992;21:409–14. 
30. Cohen F, Zuelzer WW. Identification of blood group antigens immunofluorescence and its 
application to the detection of the transplacental passage of erythrocytes  in mother and child. 
Vox Sang. 1964;9:75-8. 
31. Cohen F, Zuelzer WW. The transplacental passage of maternal erythrocytes into the fetus. Am J 
Obstet Gynecol. 1965 Oct;93:566-9. 
32. de Almeida V, Bowman JM. Massive fetomaternal hemorrhage: Manitoba experience. Obstet 
Gynecol. 1994;83:323-8 
33. Lyall F, Young A, Boswell F, Kingdom JC, Greer IA. Placental expression of vascular 
endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and 
intrauterine growth restriction does not support placental hypoxia at delivery. Placenta 
1997;18:269–76. 
34. Dye JF, Jablenska R, Donnelly JL, Lawrence L, Leach L, Clark P, et al. Phenotype of the 
endothelium in the human term placenta. Placenta 2001;22:32–43. 
35. Labarrere CA, Faulk WP. Intercellular adhesion molecule-1 (ICAM-1) and HLA-DR antigens 
are expressed on endovascular cytotrophoblasts in abnormal pregnancies. Am J Reprod 
Immunol. 1995;33:47–53 
36. Burton GJ, Tham SW. Formation of vasculo-syncytial membranes in the human placenta. J Dev 
Physiol. 1992;18:43-7. 
37. Breuning MH, van den Berg-Loonen EM, Bernini LF, Bijlsma JB, van Loghem E, Meera Khan 
P, et al. Localization of HLA on the short arm of chromosome 6. m Genet. 1977; 37:131-9. 
38. Rötzschke O, Falk K, Deres K, Schild H, Norda M, Metzger J, et al. Isolation and analysis of 
naturally processed viral peptides as recognized by cytotoxic T cells. Nature 1990;348:252-4. 
39. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands 
for T lymphocyte activation. Cell 1994;76:287-99. Review.  
 64 
 
40. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, et al. Mismatches of 
minor histocompatibility antigens between HLAidentical donors and recipients and the 
development of graftversus- host disease after bone marrow transplantation. N Engl J Med. 
1996;334:281–85. 
41. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA class I-
minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility 
antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med. 
1999;5:839–42. 
42. Zenclussen AC. Adaptive immune responses during pregnancy. Am J Reprod Immunol. 2013 
Apr;69(4):291-303. 
43. Marijt WA, Heemskerk MH, Kloosterboer FM, Goulmy E, Kester MG, van der Hoorn MA. 
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can 
induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A 2003;100:2742–47. 
44. Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor-specific 
immunotherapy. Cancer J. 2004;10:1–7. 
45. Kircher B, Stevanovic S, Urbanek M, Mitterschiffthaler A, Rammensee HG, Grunewald K. 
Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor 
lymphocyte infusion. Br J Haematol. 2002;117:935–39. 
46. Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR, et al. Therapy of relapsed 
leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor 
histocompatibility antigens. Blood 2010;115:3869–78. 
47. Barker JN, Scaradavou A, Stevens CE. Combined effect of total nucleated cell dose and HLA 
match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. 
Blood 2010;115:1843-9.  
48. Liu Z, Sun YK, Xi YP, Maffei A, Reed E, Harris P, et al. Contribution of direct and indirect 
recognition pathways to T cell alloreactivity. J Exp Med. 1993;177:1643-50. 
49. Bryder D, Rossi DJ, Weissman IL.Hematopoietic stem cells: the paradigmatic tissue-specific 
stem cell. Am J Pathol. 2006;169:338-46.  
50. Petersdorf EW Risk assessment in haematopoietic stem cell transplantation: histocompatibility. 
Best Pract Res Clin Haematol. 2007;20:155-70. Review 
51. Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, et al. Outcome 
of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic 
leukemia: no difference in related compared with unrelated transplant in first complete 
remission. J Clin Oncol. 2004;22:2816-25. 
52. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, et al. Impact of T-cell 
depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. 
Lancet 1987;2:175-8. 
53. Paulin T, Ringdén O, Nilsson B. Immunological recovery after bone marrow transplantation: 
role of age, graft-versus-host disease, prednisolone treatment and infections. Bone Marrow 
Transplant. 1987;1:317-28. 
54. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. 
Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord 
blood from an HLA-identical sibling. N Engl J Med. 1989;321:1174-8. 
55. Andersson O, Hellström-Westas L, Andersson D, Domellöf M. Effect of delayed versus early 
umbilical cord clamping on neonatal outcomes and iron status at 4 months: a randomised 
controlled trial.BMJ. 2011;343:d7157.  
 65 
 
56. Broxmeyer HE, Kurtzberg J, Gluckman E, Auerbach AD, Douglas G, Cooper S, et al. Umbilical 
cord blood hematopoietic stem and repopulating cells in human clinical transplantation. Blood 
Cells 1999;17:313-29. 
57. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, et al.Outcomes of 
transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute 
leukaemia: a comparison study. Lancet 2007;369:1947-54. 
58. Schuller CE, Jankowski K, Mackenzie KL. Telomere length of cord blood-derived CD34(+) 
progenitors predicts erythroid proliferative potential. Leukemia 2007;21:983-91.  
59. Rocha V, Crotta A, Ruggeri A, Purtill D, Boudjedir K, Herr AL, Ionescu I, et al. Double cord 
blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with 
hematological diseases. Best Pract Res Clin Haematol. 2010;23:223-9. 
60. Jaksch M, Mattsson J.The pathophysiology of acute graft-versus-host disease. Scand J Immunol. 
2005;65:398-409. Review. 
61. Billingham RE.The biology of graft-versus-host reactions. Harvey Lect. 1966-1967;62:21-78 
62. Aschan J. Treatment of moderate to severe acute graft-versus-host disease: a retrospective 
analysis. Bone Marrow Transplant. 1994;14:601-7. 
63. Siimes MA, Johansson E, Rapola J. Scleroderma-like graft-versus-host disease as late 
consequence of bone-marrow grafting. Lancet 1977;2:831-2. 
64. Atkinson K, Horowitz MM, Gale RP, van Bekkum DW, Gluckman E, Good RA, et al. Risk 
factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow 
transplantation.Blood 1990;75:2459-64. 
65. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic 
graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. 
Am J Med. 1980;69:204-17 
66. Atkinson K, Farrell C, Chapman G, Downs K, Penny R, Biggs J Female marrow donors 
increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of 
cell subpopulations in the donor marrow inoculum. Br J Haematol. 1986;63:231-9. 
67. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Antileukemic 
effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J 
Med. 1979;300:1068-73. 
68. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-
versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 
1995;86:2041-50. 
69. Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, Appelbaum FR, et al. 
Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 
1985;66:664-72. 
70. Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and 
natural killer cell recognition of missing self. Immunol Rev. 2006;214:202-18. Review. 
71. Claas FH, Gijbels Y, van der Velden-de Munck J, van Rood JJ. Induction of B cell 
unresponsiveness to noninherited maternal HLA antigens during fetal life. Science 
1998;241:1815-17. 
72. Burlingham WJ, Grailer AP, Heisey DM, Claas FH, Norman D,  Mohanakumar T, et al. The 
effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants 
from sibling donors. N Engl J Med. 1998;339:1657-64. 
73. van Rood JJ, Loberiza FR Jr, Zhang MJ, Oudshoorn M, Claas F, Cairo MS, et al. Effect of 
tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after 
bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 
2002;99:1572-7. 
 66 
 
74. Ichinohe T, Uchiyama T, Shimazaki C, Matsuo K, Tamaki S, Hino M, et al. Feasibility of HLA-
haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen 
(NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. 
Blood 2004;104:3821-8. 
75. Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C, et al. Survival after T 
cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. 
Blood 2008;112:2990-5.  
76. van Rood JJ, Stevens CE, Smits J, Carrier C, Carpenter C, Scaradavou A. Reexposure of cord 
blood to noninherited maternal HLA antigens improves transplant outcome in hematological 
malignancies. Proc Natl Acad Sci U S A 2009;106: 19952-57. 
77. Tayade C, Black GP, Fang Y, Croy BA. Differential gene expression in endometrium, 
endometrial lymphocytes, and trophoblasts during successful and abortive embryo implantation. 
J Immunol. 2006;176:148-56. 
78. von Rango U. Fetal tolerance in human pregnancy--a crucial balance between acceptance and 
limitation of trophoblast invasion. Immunol Lett. 2008;115:21-32.  
79. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, 
expressed in human trophoblasts. Science 1990;248:220-3. 
80. Parham P. NK cells and trophoblasts: partners in pregnancy. J Exp Med. 2004;200:951-5. 
81. Rouas-Freiss N, Gonçalves RM, Menier C, Dausset J, Carosella ED. Direct evidence to support 
the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc 
Natl Acad Sci U S A 1997;94:11520-5. 
82. Yao YQ, Barlow DH, Sargent IL. Differential expression of alternatively spliced transcripts of 
HLA-G in human preimplantation embryos and inner cell masses. J Immunol. 2005;175:8379-
85. 
83. Naji A, Le Rond S, Durrbach A, Krawice-Radanne I, Creput C, Daouya M, et al. CD3+CD4low 
and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell 
subsets involved in transplant acceptance. Blood 2007;110:3936-48. 
84. Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol. 2002;2:656-63. Review. 
Erratum in: Nat Rev Immunol. 2002;2:975.  
85. Singh U, Nicholson G, Urban BC, Sargent IL, Kishore U, Bernal AL. Immunological properties 
of human decidual macrophages--a possible role in intrauterine immunity. Reproduction. 
2005;129:631-7. 
86. Tilburgs T, Roelen DL, van derMast BJ, van Schip JJ, Kleijburg C, de Groot-Swings GM et al. 
Differential distribution of CD4+CD25bright and CD8+CD28− T-cells in decidua andmaternal 
blood during human pregnancy. Placenta;2006: 27:47–53 
87. Amsalem H, Gaiger A, Mizrahi S, Yagel S, Rachmilewitz J. Characterization of a lymphocyte 
subset displaying a unique regulatory activity in human decidua. Int. Immunol. 2008; 20:1147–
54. 
88. Ochanuna Z, Geiger-Maor A, Dembinsky-Vaknin A, Karussis D, Tykocinski ML, 
Rachmilewitz J. Inhibition of effector function but not T cell activation and increase in FoxP3 
expression in T cells differentiated in the presence of PP14. PLoS ONE 2010; 5:e12868. 
89. Schumacher A, Brachwitz N, Sohr S, Engeland K, Langwisch S, Dolaptchieva M, et al. Human 
chorionic gonadotropin attracts regulatory T cells into the fetal-maternal interface during early 
human pregnancy. J Immunol. 2009;182:5488–97. 
90. Nakashima A, Ito M, Shima T, Bac ND, Hidaka T, Saito S. Accumulation of IL-17-positive 
cells in decidua of inevitable abortion cases. Am. J. Reprod. Immunol. 2010; 64:4–11 
 67 
 
91. Sasaki Y, Sakai M, Miyazaki S, Higuma S, Shiozaki A, Saito S. Decidual and peripheral blood 
CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases. 
Mol. Hum. Reprod. 2006;10:347–53 
92. Sasaki Y, Darmochwal-Kolarz D, Suzuki D, Sakai M, Ito M, Shima T et al. P 
93. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead 
to different functional properties. Annual Review of Immunology, 1989;7:145–73. 
94. Wilczynski JR. Th1/Th2 cytokines balance—yin and yang of reproductive immunology. 
European Journal of Obstetrics & Gynecology and Reproductive Biology 2005;122:136–43. 
95. Piccinni MP, Giudizi MG, Biagiotti R, Beloni L, Giannarini L, Sampognaro S, et al. 
Progesterone favors the development of human T helper cells producing Th2-type cytokines and 
promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J 
Immunol. 1995;155:128-33. 
96. Huber SA, Kupperman J, Newell MK. Estradiol prevents and testosterone promotes Fas-
dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression. Lupus 1999;8:384-7. 
97. Xue L, Gyles SL, Wettey FR, Gazi L, Townsend E, Hunter MG, et al. Prostaglandin D2 causes 
preferential induction of proinflammatory Th2 cytokine production through an action on 
chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol. 2005;175:6531-6. 
98. Chaouat G. Regulation of T-cell activities at the feto-placental interface--by placenta? Am J 
Reprod Immunol. 1999;42:199-204. 
99.          Erlebacher, A., Vencato, D., Price, K.A., Zhang, D. & Glimcher, L.H. Constraints in 
antigen presentation severely restrict T cell recognition of the allogeneic fetus. J. Clin. Invest. 
2007;117:1399–411. 
100. Rowe, J.H., Ertelt, J.M., Xin, L. & Way, S.S. Pregnancy imprints regulatory memory that 
sustains anergy to fetal antigen. Nature 2012; 490:102–6. 
101. Schumacher A, Wafula PO, Bertoja AZ, Sollwedel A, Thuere C, Wollenberg I, et al. 
Mechanisms of action of regulatory T cells specific for paternal antigens during pregnancy. 
Obstet Gynecol. 2007;110:1137–45. 
102. Wafula PO, Teles A, Schumacher A, Pohl K, Yagita H, Volk HD, et al. PD-1 but not CTLA-4 
blockage abrogates the protective effect of regulatory T cells in a pregnancy murine model. Am 
J Reprod Immunol. 2009;62:283–92. 
103. Miwa N, Hayakawa S, Miyazaki S, Myojo S, Sasaki Y, Sakai M et al. IDO expression on 
decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with 
CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous 
abortion. Mol Hum Reprod. 2005;11:865–70. 
104. Robertson SA, Guerin LR, Moldenhauer LM, Hayball JD. Activating T regulatory cells for 
tolerance in early pregnancy – the contribution of seminal fluid. J Reprod Immunol. 2009; 
83:109–16. 
105. Piper KP, McLarnon A, Arrazi J, Horlock C, Ainsworth J, Kilby MD, et al. Functional HY-
specific CD8+ T cells are found in a high proportion of women following pregnancy with amale 
fetus. Biol Reprod. 2007;76:96–101. 
106. Verdijk RM, Kloosterman A, Pool J, van deKeur M, Naipal AM, van Halteren AG, et al. 
Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for 
stem cell transplantation and immunotherapy. Blood 2004;103:1961–64. 
107. van Halteren AG, Jankowska-Gan E, Joosten A, Blokland E, Pool J, et al. Naturally acquired 
tolerance and sensitization to minor histocompatibility antigens in healthy family members. 
Blood 2009;114:2263–72. 
 68 
 
108. Lissauer D, Piper K, Goodyear O, Kilby MD, Moss PA. Fetalspecific CD8+ cytotoxic T cell 
responses develop during normal human pregnancy and exhibit broad functional capacity. J 
Immunol. 2012;189:1072–80. 
109. Linscheid C, Petroff MG. Minor histocompatibility antigens and the maternal immune response 
to the fetus during pregnancy. Am J Reprod Immunol. 2013;69:304-14. Review. 
110. Christensen JL, Wright DE, Wagers AJ, Weissman IL. Circulation and chemotaxis of fetal 
hematopoietic stem cells. PLoS Biol. 2004;2:E75.  
111. Strunk T, Temming P, Gembruch U, Reiss I, Bucsky P, Schultz C. Differential maturation of the 
innate immune response in human fetuses. Pediatr Res. 2004;56:219-26. 
112. Pérez A, Gurbindo MD, Resino S, Aguarón A, Muñoz-Fernández MA. NK cell increase in 
neonates from the preterm to the full-term period of gestation. Neonatology 2007;92:158- 63. 
113. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev 
Immunol. 2007;7:379-90. Review 
114. Davies NP, Buggins AG, Snijders RJ, Jenkins E, Layton DM, Nicolaides KH. Blood leucocyte 
count in the human fetus. Arch Dis Child. 1992;67:399-403. 
115. Haynes BF.The human thymic microenvironment. Adv Immunol. 1984;36:87-142. Review. 
116. Berg LJ, Pullen AM, Fazekas de St Groth B, Mathis D, Benoist C, Davis MM. Antigen/MHC-
specific T cells are preferentially exported from the thymus in the presence of their MHC ligand. 
Cell 1989;58:1035-46. 
117. Haynes BF, Hale LP.The human thymus. A chimeric organ comprised of central and peripheral 
lymphoid components. Immunol Res. 1998;18:175-92. Review 
118. Michaëlsson J, Mold JE, McCune JM, Nixon DF. Regulation of T cell responses in the 
developing human fetus. J Immunol. 2006;176:5741-8. 
119. Kappler JW, Roehm N, Marrack P.T cell tolerance by clonal elimination in the thymus. Cell 
1987;49:273-80. 
120. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of 
developmental abnormality of a T cell subpopulation. J Exp Med. 1996;184:387-96. 
121. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and 
negative control of immune responses. Annu Rev Immunol. 2004;22:531-62. Review. 
122. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained 
by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single 
mechanism of self-tolerance causes various autoimmune diseases.J Immunol. 1995;155:1151-
64. 
123. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, et al. X-linked neonatal 
diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse 
scurfy. Nat Genet. 2001;27:18-20. 
124. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009 
;30:636-45. Review. 
125. Darrasse-Jèze G, Marodon G, Salomon BL, Catala M, Klatzmann D. Ontogeny of CD4+CD25+ 
regulatory/suppressor T cells in human fetuses. Blood 2005;105:4715-21.  
126. Cupedo T, Nagasawa M, Weijer K, Blom B, Spits H. Development and activation of regulatory 
T cells in the human fetus. Eur J Immunol. 2005:383-90. 
127. Stevens AM, Hermes HM, Kiefer MM, Rutledge JC, Nelson JL. Chimeric maternal cells with 
tissue-specific antigen expression and morphology are common in infant tissues. Pediatr Dev 
Pathol. 2009;12:337–46. 
128. Lee TH, Chafets DM, Reed W, Wen L, Yang Y, Chen J, et al. Enhanced ascertainment of 
microchimerism with real-time quantitative polymerase chain reaction amplification of 
insertion-deletion polymorphisms. Transfusion 2006;46:1870-8. 
 69 
 
129. Lambert NC, Erickson TD, Yan Z, Pang JM, Guthrie KA, Furst DE, et al. Quantification of 
maternal microchimerism by HLA-specific real-time polymerase chain reaction: studies of 
healthy women and women with scleroderma. Arthritis Rheum. 2004;50:906–14.  
130. Zhong XY, Holzgreve W, Hahn S. Direct quantification of fetal cells in maternal blood by real-
time PCR. Prenat Diagn. 2006;26:850-4. 
131. Thomas MR, Tutschek B, Frost A, Rodeck CH, Yazdani N, Craft I, et al. The time of 
appearance and disappearance of fetal DNA from the maternal circulation. Prenat Diagn. 1995 
;15:641-6. 
132. Pertl B, Bianchi DW.First trimester prenatal diagnosis: fetal cells in the maternal circulation. 
Semin Perinatol. 1999;23:393-402. 
133. Krabchi K, Gros-Louis F, Yan J, Bronsard M, Massé J, Forest JC, et al. Quantification of all 
fetal nucleated cells in maternal blood between the 18th and 22nd weeks of pregnancy using 
molecular cytogenetic techniques. Clin Genet. 2001;60:145-50. 
134. Ariga H, Ohto H, Busch MP, Imamura S, Watson R, Reed W, et al. Kinetics of fetal cellular and 
cell-free DNA in the maternal circulation during and after pregnancy: implications for 
noninvasive prenatal diagnosis. Transfusion. 2001;41:1524-30. 
135. O’Donoghue K, Chan J, de la FJ, Kennea N, Sandison A, Anderson JR, et al. Microchimerism 
in female bone marrow and bone decades after fetal mesenchymal stem cell trafficking in 
pregnancy. Lancet 2004;364:179 82. 
136. Bianchi DW, Williams JM, Sullivan LM, Hanson FW, Klinger KW,et al. PCR quantitation of 
fetal cells in maternal blood in normal and aneuploid pregnancies. Am J Hum Genet. 
1997;61:822-9. 
137. Krabchi K, Gadji M, Forest JC, Drouin R. Quantification of all fetal nucleated cells in maternal 
blood in different cases of aneuploidies. Clin Genet. 2006;69:145-54. 
138. Holzgreve W, Ghezzi F, Di Naro E, Gänshirt D, Maymon E, Hahn S. Disturbed feto-maternal 
cell traffic in preeclampsia. Obstet Gynecol. 1998 May;91(5 Pt 1):669-72. 
139. Swinkels DW, de Kok JB, Hendriks JC, Wiegerinck E, Zusterzeel PL, Steegers EA. Hemolysis, 
elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of 
preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA in 
maternal plasma and serum. Clin Chem. 2002;48(4):650-3. 
140. Leung TN, Zhang J, Lau TK, Hjelm NM, Lo YM. Maternal plasma fetal DNA as a marker for 
preterm labour. Lancet 1998;352:1904-5. 
141. Al-Mufti R, Lees C, Albaiges G, Hambley H, Nicolaides KH. Fetal cells in maternal blood of 
pregnancies with severe fetal growth restriction. Hum Reprod. 2000;15:218-21. 
142. O'Donoghue K, Choolani M, Chan J, de la Fuente J, Kumar S, Campagnoli C, et al. 
Identification of fetal mesenchymal stem cells in maternal blood: implications for non-invasive 
prenatal diagnosis. Mol Hum Reprod. 2003 ;9:497-502. 
143. Evans PC, Lambert N, Maloney S, Furst DE, Moore JM, Nelson JL. Long-term fetal 
microchimerism in peripheral blood mononuclear cell subsets in healthy women and women 
with scleroderma. Blood 1999 ;93:2033-7. 
144. Cuddapah Sunku C, Gadi V, de Laval de Lacoste B, Guthrie K, Nelson J. Maternal and fetal 
microchimerism in granulocytes. Chimerism 2010;1:11–4. 
145. Srivatsa B, Srivatsa S, Johnson KL, Samura O, Lee SL, Bianchi DW. Microchimerism of 
presumed fetal origin in thyroid specimens from women: a case-control study. Lancet 
2001;358:2034-8. 
146. Ohtsuka T, Miyamoto Y, Yamakage A, Yamazaki S. Quantitative analysis of microchimerism 
in systemic sclerosis skin tissue. Arch Dermatol Res. 2001;293:387-91. 
 70 
 
147. Koopmans M, Kremer Hovinga IC, Baelde HJ, Harvey MS, de Heer E, Bruijn JA, Bajema IM. 
Chimerism occurs in thyroid, lung, skin and lymph nodes of women with sons. J Reprod 
Immunol. 2008;78:68-75. 
148. Koopmans M, Kremer Hovinga IC, Baelde HJ, Fernandes RJ, de Heer E, Bruijn JA, Bajema 
IM. Chimerism in kidneys, livers and hearts of normal women: implications for transplantation 
studies. Am J Transplant. 2005 Jun;5(6):1495-502. 
149. Stevens AM, McDonnell WM, Mullarkey ME, Pang JM, Leisenring W, Nelson JL. Liver 
biopsies from human females contain male hepatocytes in the absence of transplantation. Lab 
Invest. 2004;84(12:1603-9. 
150. Bayes-Genis A, Bellosillo B, de la Calle O, Salido M, Roura S, Ristol FS, Soler C, Martinez M, 
Espinet B, Serrano S, Bayes de Luna A, Cinca J. Identification of male cardiomyocytes of 
extracardiac origin in the hearts of women with male progeny: male fetal cell microchimerism 
of the heart. J Heart Lung Transplant. 2005;24:2179-83. 
151. Khosrotehrani K, Johnson KL, Cha DH, Salomon RN, Bianchi DW. Transfer of fetal cells with 
multilineage potential to maternal tissue. JAMA 2004;292:75-80. 
152. Guettier C, Sebagh M, Buard J, Feneux D, Ortin-Serrano M, Gigou M, et al. Male cell 
microchimerism in normal and diseased female livers from fetal life to adulthood . Hepatology 
2005;42:35–43. 
153. Bayes-Genis A, Roura S, Prat-Vidal C, Farré J, Soler-Botija C, de Luna AB, et al. Chimerism 
and microchimerism of the human heart: evidence for cardiac regeneration. Nat Clin Pract 
Cardiovasc Med. 2007;4: 40-5. 
154. Cirello V, Perrino M, Colombo C, Muzza M, Filopanti M, Vicentini L, et al. Fetal cell 
microchimerism in papillary thyroid cancer: studies in peripheral blood and tissues. Int J Cancer  
2010;126:2874-8.  
155. Silman AJ.Epidemiology of scleroderma.Curr Opin Rheumatol. 1991;3:967-72. Review 
156. Nelson JL, Furst DE, Maloney S, Gooley T, Evans PC, et al. Microchimerism and HLA-
compatible relationships of pregnancy in scleroderma. Lancet 1998;351:559–62. 
157. Lambert NC, Lo YM, Erickson TD, Tylee TS, Guthrie KA, Furst DE Male microchimerism in 
healthy women and women with scleroderma: cells or circulating DNA? A quantitative answer. 
Blood 2002;100:2845–51.  
158. Johnson KL, McAlindon TE, Mulcahy E, Bianchi DW. Microchimerism in a female patient 
with systemic lupus erythematosus. Arthritis Rheum. 2001; 44:2107–11. 
159. Artlett CM, Smith JB, Jimenez SA. Identification of fetal DNA and cells in skin lesions from 
women with systemic sclerosis. N Engl J Med. 1998;338:1186-91. 
160. Murata H, Nakauchi H, Sumida T. Microchimerism in Japanese women patients with systemic 
sclerosis. Lancet;1999;354:220. 
161. Gannagé M, Amoura Z, Lantz O, Piette JC, Caillat-Zucman S. Feto-maternal microchimerism in 
connective tissue diseases. Eur J Immunol. 2002;32:3405-13. 
162. Nelson JL.Microchimerism: incidental byproduct of pregnancy or active participant in human 
health? Trends Mol Med. 2002;8:109-13. 
163. Fanning PA, Jonsson JR, Clouston AD, Edwards-Smith C, Balderson GA, Macdonald GA, et al. 
Detection of male DNA in the liver of female patients with primary biliary cirrhosis. J Hepatol. 
2000;33:690-5. 
164. Tanaka A, Lindor K, Gish R, Batts K, Shiratori Y, Omata M, et al. Fetal microchimerism alone 
does not contribute to the induction of primary biliary cirrhosis. Hepatology1999;30:833-8. 
165. Invernizzi P, De Andreis C, Sirchia SM, Battezzati PM, Zuin M, Rossella F, et al. Blood fetal 
microchimerism in primary biliary cirrhosis. Clin Exp Immunol. 2000;122:418-22. 
 71 
 
166. Kuroki M, Okayama A, Nakamura S, Sasaki T, Murai K, Shiba R, et al. Detection of maternal-
fetal microchimerism in the inflammatory lesions of patients with Sjögren's syndrome. Ann 
Rheum Dis. 2002;61:1041-6. 
167. Toda I, Kuwana M, Tsubota K, Kawakami Y.Lack of evidence for an increased 
microchimerism in the circulation of patients with Sjögren's syndrome. Ann Rheum Dis. 
2001;60:248-53. 
168. Klintschar M, Immel UD, Kehlen A, Schwaiger P, Mustafa T, Mannweiler S, et al. Fetal 
microchimerism in Hashimoto's thyroiditis: a quantitative approach. Eur J Endocrinol. 
2006;154:237-41. 
169. Johnson KL, Samura O, Nelson JL, McDonnell M d WM, Bianchi DW. Significant fetal cell 
microchimerism in a nontransfused woman with hepatitis C: Evidence of long-term survival and 
expansion. Hepatology. 2002;36:1295-7.  
170. Hromadnikova I, Zlacka D, Hien Nguyen TT, Sedlackova L, Zejskova L, Sosna A. Fetal cells of 
mesenchymal origin in cultures derived from synovial tissue and skin of patients with 
rheumatoid arthritis. Joint Bone Spine. 2008;75:563-6. 
171. Mosca M, Curcio M, Lapi S, Valentini G, D’Angelo S, Rizzo G, et al. Correlations of Y 
chromosome microchimerism with disease activity in patients with SLE: Analysis of 
preliminary data. Ann Rheum Dis. 2003;62:651 4. 
172. Yu J, Ren X, Cao S, Li H, Hao X. Beneficial effects of fetal-maternal microchimerism on the 
activated haplo-identical peripheral blood stem cell treatment for cancer. Cytotherapy 
2008;(4):331-9. 
173. Gadi VK, Nelson JL. Fetal microchimerism in women with breast cancer. Cancer Res. 
2007;67:9035-8. 
174. Gadi VK, Malone KE, Guthrie KA, Porter PL, Nelson JL. Case-control study of fetal 
microchimerism and breast cancer. PLoS One 2008;3:e1706.  
175. Gadi VK. Fetal microchimerism and cancer. Cancer Lett. 2009;276:8-13. 
176. Cha D, Khosrotehrani K, Kim Y, Stroh H, Bianchi DW, Johnson KL. Cervical cancer and 
microchimerism. Obstet Gynecol. 2003;102:774-81. 
177. O'Donoghue K, Sultan HA, Al-Allaf FA, Anderson JR, Wyatt-Ashmead J, Fisk NM. 
Microchimeric fetal cells cluster at sites of tissue injury in lung decades after pregnancy. Reprod 
Biomed Online 2008;16:382-90. 
178. Cirello V, Recalcati MP, Muzza M, Rossi S, Perrino M, Vicentini L, et al. Fetal cell 
microchimerism in papillary thyroid cancer: a possible role in tumor damage and tissue repair. 
Cancer Res. 2008;68:8482-8.  
179. Pollack MS, Kapoor N, Sorell M, Kim SJ, Christiansen FT, Silver DM, et al. DR-positive 
maternal engrafted T cells in a severe combined immunodeficiency patient without graft-versus-
host disease.Transplantation. 1980;30:331-4. 
180. Müller SM, Ege M, Pottharst A, Schulz AS, Schwarz K, Friedrich W.Transplacentally acquired 
maternal T lymphocytes in severe combined immunodeficiency: a study of 121 patients. Blood 
2001;98:1847-51. 
181. Geha RS, Reinherz E. Identification of circulating maternal T and B lymphocytes in 
uncomplicated severe combined immunodeficiency by HLA typing of subpopulations of T cells 
separated by the fluorescence-activated cell sorter and of Epstein Barr virus-derived B cell lines. 
J Immunol. 1983;130:2493-5. 
182. Reed AM, Picornell YJ, Harwood A, Kredich DW. Chimerism in children with juvenile 
dermatomyositis. Lancet 2000;356:2156–57.  
183. Reed AM, McNallan K, Wettstein P, Vehe R, Ober C. Does HLA-dependent chimerism 
underlie the pathogenesis of juvenile dermatomyositis?. J Immunol.  2004;172:5041–46.  
 72 
 
184. Ye Y, van Zyl B, Varsani H, Wedderburn LR, Ramanan A, Gillspie KM, et al. Maternal 
microchimerism in muscle biopsies from children with juvenile dermatomyositis. Juvenile 
Dermatomyositis Research Group. Rheumatology (Oxford) 2012;51: 987–91. 
185. Artlett CM, Ramos R, Jiminez SA, Patterson K, Miller FW, Rider LG. Chimeric cells of 
maternal origin in juvenile idiopathic inflammatory myopathies. Lancet 2000; 356:2155–56.  
186. Artlett CM, Miller FW, Rider LG. Persistent maternally derived peripheral microchimerism is 
associated with the juvenile idiopathic inflammatory myopathies. Childhood Myositis 
Heterogeneity Collaborative Study Group. Rheumatology 2001;40: 1279–84. 
187. Stevens AM, Hermes HM, Rutledge JC, Buyon JP, Nelson JL. Myocardial-tissue-specific 
phenotype of maternal microchimerism in neonatal lupus congenital heart block. Lancet 
2003;362:1617–23. 
188. Nelson JL, Gillespie KM, Lambert NC, Stevens AM, Loubiere LS, Rutledge JC, et al. Maternal 
microchimerism in peripheral blood in type 1 diabetes and pancreatic islet beta cell 
microchimerism. Proc Natl Acad Sci USA 2007;104:1637–42. 
189. Khosrotehrani K, Guegan S, Fraitag S, Oster M, de Prost Y, Bodemer C, et al. Presence of 
chimeric maternally derived keratinocytes in cutaneous inflammatory diseases of children: the 
example of pityriasis lichenoides. J Invest Dermatol. 2006;126:345–48.  
190. Suskind DL, Rosenthal P, Heyman MB, Kong D, Magrane G, Baxter-Lowe LA, et al. Maternal 
microchimerism in the livers of patients with biliary atresia. BMC Gastroenterol. 2004;4:14.  
191. Lo ES, Lo YM, Hjelm NM, Thilaganathan B.Transfer of nucleated maternal cells into fetal 
circulation during the second trimester of pregnancy. Br J Haematol. 1998;3:605-6. 
192. Kögler G, Göbel U, Somville T, Enczmann J, Arkesteijn G, Wernet P. et al. Simultaneous 
genotypic and immunophenotypic analysis of interphase cells for the detection of contaminating 
maternal cells in cord blood and their respective CFU-GM and BFU-E.J Hematother Summer 
1993;2:235-39. 
193. Wernet P, Kögler G, Somville T. The rapid detection of the quantity (genotype) and cell lineage 
(immunophenotype) of contaminating maternal white cells in cord blood samples by 
fluorescence in situ hybridization combined with confocal laser scanning microscopy. Blood 
Cells. 1994;20:296-302. 
194. Socié G, Gluckman E, Carosella E, Brossard Y, Lafon C, Brison O. Search for maternal cells in 
human umbilical cord blood by polymerase chain reaction amplification of two minisatellite 
sequences. Blood 1994;83:340-4. 
195. Petit T, Gluckman E, Carosella E, Brossard Y, Brison O,Socié G. A highly sensitive polymerase 
chain reaction method reveals the ubiquitous presence of maternal cells in human umbilical cord 
blood. Exp Hematol. 1995;23:1601-5. 
196. Hall JM, Lingenfelter P, Adams SL, Lasser D, Hansen JA, Bean MA, et al. Detection of 
maternal cells in human umbilical cord blood using fluorescence in situ hybridization. Blood 
1995;86: 2829-32. 
197. Lo YM, Lo ES, Watson N, Noakes L, Sargent IL,  Thilaganathan B, et al. Two-way cell traffic 
between mother and fetus: biologic and clinical implications. Blood 1996;88:4390-5. 
198. Scaradavou A, Carrier C, Mollen N, Stevens C, Rubinstein P. Detection of maternal DNA in 
placental/umbilical cord blood by locus-specific amplification of the noninherited maternal 
HLA gene. Blood 1996; 88:1494-1500. 
199. Briz M, Regidor C, Monteagudo D, Somolinos N, Garaulet C, Forés R, et al. Detection of 
maternal DNA in umbilical cord blood by polymerase chain reaction amplification of 
minisatellite sequences. Bone Marrow Transplant 1998;21:1097-9. 
 73 
 
200. Berry SM, Hassan SS, Russell E, Kukuruga D, Land S, et al. Association of maternal 
histocompatibility at class II HLA loci with maternal microchimerism in the fetus. Pediatr Res. 
2004; 56:73–8.  
201. Loubière LS, Lambert NC, Flinn LJ, Erickson TD, Yan Z, Guthrie KA, et al. Maternal 
microchimerism in healthy adults in lymphocytes, monocyte/macrophages and NK cells. Lab 
Invest. 2006;86:1185-92.  
202. Götherstrom C, Johnsson AM, Mattsson J, Papadogiannakis N, Westgren M. Identification of 
maternal hematopoietic cells in a 2nd-trimester fetus. Fetal Diagn Ther. 2005;20:355-8. 
203. Srivatsa B, Srivatsa S, Johnson KL, Bianchi DW. Maternal cell microchimerism in newborn 
tissues. J Pediatr. 2003;142:31–5. 
204. Buyon JP, Clancy RM. Maternal autoantibodies and congenital heart block: mediators, markers, 
and therapeutic approach. Semin Arthritis Rheum. 2003;33:140-54. Review.  
205. Tomasini D, Tomasini CF, Cerri A, Sangalli G, Palmedo G, Hantschke M, et al. Pityriasis 
lichenoides: a cytotoxic T-cell-mediated skin disorder. Evidence of human parvovirus B19 
DNA in nine cases. J Cutan Pathol. 2004 Sep;31(8):531-8. 
206. Vanzyl B, Planas R, Ye Y, Foulis A, de Krijger RR, Vives-Pi M, et al. Why are levels of 
maternal microchimerism higher in type 1 diabetes pancreas? Chimerism. 2010;1:45-50. 
207. Reed AM, Pachman L, Ober C. Molecular genetic studies of major histocompatibility complex 
genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1 
*0501. Hum Immunol. 1991;32:235-40. 
208. Pedrol E, Grau JM, Casademont J, Cid MC, Masanés F, Fernandez-Sola J, et al. Idiopathic 
inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility 
complex antigen expression, inflammatory infiltrate phenotype and activation cell markers. Clin 
Neuropathol. 1995;14:179-84. 
209. Kobayashi H, Tamatani T, Tamura T, Kusafuka J, Yamataka A, et al. Maternal microchimerism 
in biliary atresia. J Pediatr Surg. 2007;42: 987-91.  
210. Hayashida M, Nishimoto Y, Matsuura T, Takahashi Y, Kohashi K, Souzaki R, et al. The 
evidence of maternal microchimerism in biliary atresia using fluorescent in situ hybridization. J 
Pediatr Surg. 2007;42:2097–101. 
211. Muraji T, Suskind DL, Irie N. Biliary atresia: a new immunological insight into 
etiopathogenesis. Expert Rev Gastroenterol Hepatol. 2009;3:599-606.  
212. Leveque L, Khosrotehrani K. Can maternal microchimeric cells influence the fetal response 
toward self antigens? Chimerism. 2011;2:71-7. 
213. Rak JM, Maestroni L, Balandraud N, Guis S, Boudinet H, Guzian MC, et al. Transfer of the 
shared epitope through microchimerism in women with rheumatoid arthritis. Arthritis Rheum. 
2009;60:73-80.  
214. ten Wolde S, Breedveld FC, de Vries RR, D'Amaro J, Rubenstein P, Schreuder GM, et al. 
Influence of non-inherited maternal HLA antigens on occurrence of rheumatoid arthritis. Lancet 
23;341:200-2. 
215. Harney S, Newton J, Milicic A, Brown MA, Wordsworth BP. Non-inherited maternal HLA 
alleles are associated with rheumatoid arthritis. Rheumatology (Oxford) 2003;42:171-4. 
216. de Lavareille A, Michel O, Heimann P, Cogan E, Goldman M, Roufosse e. Chronic GVH-like 
disease in a man exposed to organic solvents: evidence for a role of microchimeric cells of 
maternal origin . Clinical Immunol. 2005; S1:11. 
217. Lambert NC, Pang JM, Yan Z, Erickson TD, Stevens AM, Furst DE, et al. Male 
microchimerism in women with systemic sclerosis and healthy women who have never given 
birth to a son. Ann Rheum Dis. 2005;64:845-8. 
 74 
 
218. Yan Z, Lambert NC, Guthrie KA, Porter AJ, Loubiere LS, Madeleine MM, et al. Male 
microchimerism in women without sons: quantitative assessment and correlation with 
pregnancy history. Am J Med. 2005 Aug;118:899-906. 
219. Gannagé M, Amoura Z, Lantz O, Piette JC, Caillat-Zucman S. Feto-maternal microchimerism in 
connective tissue diseases. Eur J Immunol. 2002;32:3405-13. 
220. Peterson SE, Nelson JL, Guthrie KA, Gadi VK, Aydelotte TM, Oyer DJ, et al. Prospective 
assessment of fetal-maternal cell transfer in miscarriage and pregnancy termination. Hum 
Reprod. 2012;27:2607-12.  
221. Guettier C, Sebagh M, Buard J, Feneux D, Ortin-Serrano M, Gigou M, et al. Male cell 
microchimerism in normal and diseased female livers from fetal life to adulthood.Hepatology. 
2005;42:35-43. 
222. Dierselhuis MP, Blokland EC, Pool J, Schrama E, Scherjon SA, Goulmy E. Transmaternal cell 
flow leads to antigen-experienced cord blood. Blood 2012;120:505-10.  
223. Hall JG.Twinning. Lancet 2003;362:735-43. Review. 
224. Zhou L, Yoshimura Y, Huang Y, Suzuki R, Yokoyama M, Okabe M, et al. Two independent 
pathways of maternal cell transmission to offspring: through placenta during pregnancy and by 
breast-feeding after birth. Immunology. 2000;101:570-80. 
225. Aoyama K, Koyama M, Matsuoka K, Hashimoto D, Ichinohe T, Harada M, et al. Improved 
outcome of allogeneic bone marrow transplantation due to breastfeeding-induced tolerance to 
maternal antigens. Blood 2009 ;1 13:1829-33. 
226. Andrassy J, Kusaka S, Jankowska-Gan E, Torrealba JR, Haynes LD, Marthaler BR, et al. 
Tolerance to noninherited maternal MHC antigens in mice. J Immunol. 2003;171:5554-61. 
227. Twigger AJ, Hodgetts S, Filgueira L, Hartmann PE, Hassiotou F. From breast milk to brains: the 
potential of stem cells in human milk. J Hum Lact. 2013;29:136-9. 
228. Fujiki, Y., Johnson, K. L., Tighiouart, H., Peter, I., and Bianchi, D. W. Fetomaternaltrafficking 
in the mouse increases as delivery approaches and is highest in the maternal lung. Biol. Reprod. 
2008;79:841–848. 
229. Piotrowski P, Croy BA. Maternal cells are widely distributed in murine fetuses in utero. Biol 
Reprod. 1996;54:1103-10. 
230. Kaplan J, Land S.Influence of maternal-fetal histocompatibility and MHC zygosity on maternal 
microchimerism.J Immunol. 2005;174:7123-8. 
231. Malassiné A, Frendo JL, Evain-Brion D. A comparison of placental development and endocrine 
functions between the human and mouse model. Hum Reprod Update 2003;9:531-9. 
232. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al. The 1982 revised criteria for the 
classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25: 1271–7.  
233. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus 
erythematosus activity in clinical research. Arthritis Rheum. 31:1988;817–25.  
234. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, et al. The development and initial 
validation of the Systemic Lupus International Collaborating Clinics/American College of 
Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–
369.  
235. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL. et al. International consensus 
statement on an update of the classification criteria for definite antiphospholipid syndrome 
(APS). J Thromb Haemost. 2006; 4:295–306.  
236. Mattsson J, Uzunel M, Remberger M, Ringden O. T cell mixed chimerism is significantly 
correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell 
transplantation. Transplantation 2001;71:433-9. 
 75 
 
237. Mergenthaler S, Babochkina T, Kiefer V, Lapaire O, Holzgreve W, Hahn S. FISH analysis of all 
fetal nucleated cells in maternal whole blood: improved specificity by the use of two Y-
chromosome probes. J Histochem Cytochem. 2005;53:319–22. 
238. Sedlmayr P, Kroneis T.Verification of the genomic identity of candidate microchimeric cells. 
Chimerism 2011 Jul;2:63-4.  
239. Adams GB, Scadden DT.The hematopoietic stem cell in its place. Nat Immunol. 2006;7:333-7. 
Review. 
240. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, et al. Circ Res. Bone marrow 
origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological 
and pathological neovascularization. 1999;85:221-8. 
241. Cogle CR, Yachnis AT, Laywell ED, Zander DS, Wingard JR, Steindler DA, et al. Bone 
marrow transdifferentiation in brain after transplantation: a retrospective study. Lancet 
2004;363:1432-7. 
242. Körbling M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, et al. Hepatocytes and 
epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med. 
2002;346:738-46. 
243. Bittner RE, Schöfer C, Weipoltshammer K, Ivanova S, Streubel B, Hauser E, et al. Recruitment 
of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. 
Anat Embryol (Berl). 1999;199:391-6. 
244. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells 
regenerate infarcted myocardium. Nature 2001;410:701-5. 
245. Borue X, Lee S, Grove J, Herzog EL, Harris R, Diflo T, et al. Bone marrow-derived cells 
contribute to epithelial engraftment during wound healing. Am J Pathol. 2004;165:1767-72. 
246. Jiang S, Walker L, Afentoulis M, Anderson DA, Jauron-Mills L, Corless CL, et al. Transplanted 
human bone marrow contributes to vascular endothelium. Proc Natl Acad Sci U S A. 
2004;101:16891-6.  
247. Gammill HS, Adams Waldorf KM, Aydelotte TM, Lucas J, Leisenring WM, Lambert NC, et al. 
Pregnancy, microchimerism, and the maternal grandmother. PLoS One 2011;6:e24101.  
248. Kusters MA, Verstegen RH, Gemen EF, de Vries E. Intrinsic defect of the immune system in 
children with Down syndrome: a review. Clin Exp Immunol. ;156:189-93. 
249. McClory S, Hughes T, Freud AG, Briercheck EL, Martin C, Trimboli AJ, et al. Evidence for a 
stepwise program of extrathymic T cell development within the human tonsil. J Clin Invest. 
2012;122:1403-15. 
250. Dutta P, Molitor-Dart M, Bobadilla JL, Roenneburg DA, Yan Z, Torrealba JR, et al. 
Microchimerism is strongly correlated with tolerance to noninherited maternal antigens in mice. 
Blood 2009;114:3578-87.  
251. Dalle JH, Menezes J, Wagner E, Blagdon M, Champagne J, Champagne MA, et al. 
Characterization of cord blood natural killer cells: implications for transplantation and neonatal 
infections. Pediatr Res. 2005;57:649-55.  
252. Fialkow PJ, Gilchrist C, Allison AC. Autoimmunity in chronic graft-versus-host disease. Clin 
Exp Immunol. 1973;13:479-86. 
253. Rouquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A. Autoimmunity in 28 
patients after allogeneic bone marrow transplantation: comparison with Sjögren syndrome and 
scleroderma. Br J Haematol. 1987;66:45-7 
254. Stevens AM, Tsao BP, Hahn BH, Guthrie K, Lambert NC, et al. Maternal HLA class II 
compatibility in men with systemic lupus erythematosus. Arthritis Rheum. 2005 Sep;52:2768-
73. 
 76 
 
255. Kremer Hovinga IC, Koopmans M, Baelde HJ, de Heer E, Bruijn JA, et al. Tissue chimerism in 
systemic lupus erythematosus is related to injury. Ann Rheum Dis. 2007;66:1568–73. 
256. Johnson KL, McAlindon TE, Mulcahy E, Bianchi DW. Microchimerism in a female patient 
with systemic lupus erythematosus. Arthritis Rheum.44:2107–11. 
257. Thompson EE, Myers RA, Du G, Aydelotte TM, Tisler CJ, et al. Maternal microchimerism 
protects against the development of asthma. J Allergy Clin Immunol. 2013;132:39-44.  
258. Azzouz DF, Rak JM, Balandraud N, Auger I, Martin M, Roudier J, et al. How microchimerism 
can impart HLA susceptibility to rheumatoid arthritis. Chimerism 2010;1:23-5. 
259. Artlett CM, Miller FW, Rider LG. Persistent maternally derived peripheral microchimerism is 
associated with the juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 
2001;40:1279-84. 
 
 
 
 
 
